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Glycan Characterization and Manipulation using Phospholipid Additives for
Capillary Electrophoresis
Stephanie A. Archer-Hartmann

Protein glycosylation is of interest in a number of emerging fields, and plays
important functional roles in cellular biology. The analysis of these molecules is
nontrivial because they exhibit great complexity in both monomer makeup and linkages
of these monomers. As a result, a common challenge that analytical techniques face is the
separation of linkage glycan isomers.

This dissertation is based on the research leading

to the development of a phospholipid-capillary electrophoresis method that allows for
highly efficient separations and the non-covalent incorporation of enzymes and lectins for
in-capillary interactions. Glycans were removed from glycoproteins through enzymatic
means, then labeled with the fluorescent tag 9- aminopyrene-1,3,6-trisulfonic acid. This
label provides charge to the otherwise neutral glycan, as well as the very low limits of
detection (15fM) that laser induced fluorescence detection affords. Separations
efficiencies, based on hydrodynamic volume, were as high as 640,000 theoretical plates.
These methods not only provide superior separations efficiencies, but also crucial
structural information about the glycans themselves. This method is amenable for a wide
variety of lectins/enzymes for use, and has been conducted in a number of different
capillary inner diameters. The method was used to probe glycans solutions taken from
MCF7 immortalized breast cancer cells, as well as glycans from the therapeutic antibody,
Trastuzumab. Only microgram amounts of these proteins were need to provide the
glycans necessary for analysis. These samples display a number of high and low

abundance glycans that were well resolved. The identity of these glycans were confirmed
with the use of glycan standards as well as a number of monomer and linkage-specific
enzymes and lectins. Multiple enzymes may be used singly, or in tandem, to
systematically remove glycan monomers and discern layers of information about the
glycans in use.
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Chapter 1

Introduction to Capillary Electrophoresis, Phospholipid
Materials, and Glycans

1

1.0 Introduction

Capillary electrophoresis (CE) is a rapid separations method that provides high
resolution and separation efficiencies. CE is well suited for the separations of biological
molecules because as a microscale technique it uses very low volumes of analyte per
analysis. With optical methods such as laser induced fluorescence (LIF), low limits of
detection may be achieved. CE separations have been used in the analysis of glycans
[1-4]. Recently phospholipid additives were incorporated into CE separations for the
separation of glycans [5]. This research explored the effects of temperature, phospholipid
content, and composition on the performance of the separation. The use of phospholipid
media is attractive for CE separations because it separates glycans efficiently and the
material is easily incorporated into separation capillaries.
The research covered in this body of work further investigates the use of
phospholipid additives in CE for the analysis of glycans. This research documents the
expanded and practical applications of this separations technique. Chapter 1 discusses the
fundamentals of capillary electrophoresis, phospholipid materials, and glycans. Previous
work by Luo et al demonstrated the first use of phospholipids in capillary electrophoresis
for the analysis of glycans. Chapter 2 covers the expanded optimization of glycan
separations since that first publication. It covers the effects of modified injection protocol
and separation conditions for on-column detection. Chapter 3 covers the expansion of the
existing separation methodology to include glycan-specific selectors such as enzymes and
lectins, for on-capillary analysis of glycans. Finally, these methods are applied to the real

2

world samples of glycans taken from MCF7 immortalized breast cancer cells and the
therapeutic antibody Trastuzumab in Chapter 4. This work covers research that has been
published in:
Archer-Hartmann, S.A., Crihfield, C.L., Holland, L.A., On-Line Enzymatic Sequencing of
Glycans from Trastuzumab by Phospholipid Capillary Electrophoresis, Electrophoresis,
2011. accepted

Archer-Hartmann, S.A., Sargent, L.M., Lowry, D.T., Holland, L.A., Microscale
Exoglycosidases Processing and Lectin Capture of Glycans with Phospholipid Assisted
Capillary Electrophoresis Separations, Analytical Chemistry, 2011. 83: p. 2740-2747

Luo, R., Archer-Hartmann, S.A., Holland, L.A., Transformable Capillary Electrophoresis
for Oligosaccharide Separations Using Phospholipid Additives, Analytical Chemistry,
2010. 82: p. 1228-1233

1.1.1 Theory of Capillary Electrophoresis
To better understand the separations processes that make the developed methods
described in subsequent chapters possible, this section will cover the basics of capillary
electrophoresis (CE). CE was first reported in the 1980s by the Jorgenson group [6,7]. CE
is characterized as providing rapid, efficient separations of molecules based on their
charge-to-size ratios. Applications of CE methodologies include profiling a number of
analytes in bioanalysis such small molecule pharmaceuticals, analysis of peptides and
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proteins, oligonucleotides, and DNA [8]. A number of methods exist in the capillary
electrophoresis family including capillary isotachophoresis (CITP), capillary isoelectric
focusing (CIEF), micellar electrokinetic capillary chromatography (MEKC), and
capillary gel electrophoresis (CGE). Additionally methods for capillary electrophoresis
can be easily adapted to microfluidic methods for the development of portable and
disposable means of analysis.

1.1.2 Instrumentation of Capillary Electrophoresis
At its most fundamental, CE instrumentation is comprised of three general parts: a
narrow bore (~10 to 100µm i.d.) capillary made from fused silica that is filled with and
held between two buffer vials, a power supply to provide voltage, and a method of
detection. The fused silica capillary is narrow bore and is often coated in polyimide to
prevent breakage. The capillary can be cut to a specified length with a ceramic cutter. To
prepare a window for optical modes of detection, a propane or butane torch is frequently
used to remove a small segment of the the polyimide coating. The placement of anode inlet

and cathode-outlet to the capillary for separation is known as normal polarity.

Switching the the cathode and anode for separation (cathode-inlet and anode-outlet) is
known as a reverse polarity separation. Commercial instrumentation often incorporates
methods of automated sample handling, as well as methods of temperature control for the
samples and thermostatting of the capillary.

Commercial CE instruments are often

available with a number of pre-equipped detection modes, such as UV-absorbance
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detection or laser induced fluorescence (LIF). Commercial CE instruments also are
amenable for on-line coupling to electrospray ionization-mass spectrometry.
Following the application of voltage within the capillary, analytes are separated
and eluted, based on their charge-to-size ratio. Figure 1-1 provides the basic schematic
for this instrument, as well as a basic electropherogram readout.

to detector

-

+

buffer (or sample) vials

HVPS

signal

time

y, October 24, 2011

Figure 1-1: Schematic of CE instrument and Electropherogram: Figure 1 shows
the basic schematic of a capillary electrophoresis instrument including a fused silica
capillary held between two buffer vials attached to a high voltage power supply. Also
shown is a representation of an electropherogram showing the separation of three
analytes.
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1.1.3 Electrophoretic Mobility and Electroosmotic Flow
When a voltage is applied to the capillary, the analytes within it move as a result
of their electrophoretic mobility. This mobility is direction dependent, negatively charged
species will migrate toward the anode, while positively charged species will migrate
toward the cathode. The velocity of this migration is dependent on the analytes’ chargeto-size ratio and can be further described as
µ = q / (6πηr)

(1-1)

where q is the net charge of the analyte, η s the viscosity of the separations media or
buffer, and r is the hydrodynamic radius of the analyte. During separation, the various
analytes within the capillary will separate based on their individual electrophoretic
mobilities as discrete bands or zones. This separation method is known as capillary zone
electrophoresis. During separation, molecules that are net positive, net negative, or
neutral all migrate to the detection window. This indicates that there is secondary force at
work within the separations capillary. This force, known as electroosmotic flow, occurs as
a result of the charged nature of the fused silica capillary inner wall. The silica surface
imparts charge in the form of negative silanol groups in a buffer solution. This charge
attracts positive ions from the buffer solution that forms two discrete layers, known as an
electronic double layer. The first, known as the Stern layer, is a thin layer of positively
charged ions that lays static against the silanol groups. The second, less dense layer of
positive ions is known as the Outer Helmoltz plane (OHP). Under an applied voltage, this
diffuse layer will migrate toward the cathode, pulling waters of hydration with it. Due to
the small inner diameters inherent to CE, this action results in a bulk flow through the
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capillary. Electroosmotic flow, also known as EOF, provides a nonmechanical method of
liquid flow through the capillary, and boasts a plug-like fluid flow profile that results in
less band broadening than that of hydrodynamic flow. However, EOF is frequently a
challenge to reproducibly control. EOF flow rates that are too small result in long
migration times and increased time-dependent band broadening for neutral and negative
species. EOF flow rates that are too fast result in analytes reaching the detector before
they have adequate time to separate. The magnitude of EOF is dependent on both the pH,
and ionic strength of the separations buffer. It is common practice in capillary zone
electrophoresis to include a known neutral analyte standard as a means to monitor the
electroosmotic flow. A simplified schematic of how electrophoretic mobility and
electroosmotic result in the separation of analytes is shown in Figure 1-2.

-------------------+++++++++++++++++++++++++++
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+
+
-+
+
N
-++
-++
+
N
++
+++++++++++++++++++++++++++
-------------------N

N

N

Figure 1-2 shows the migration of ions in capillary electrophoresis. An electronic
double layer forms at the wall of the capillary, which is the impetus for a bulk
electroosmotic flow. Analytes separate due to their individual electrophoretic mobilities,
which are due to the charge and size of the analyte.

Chapter 2 Figure 1
7

1.1.4 Resolution of Analytes in CE

The simplest way to characterize the separation of two bands of analyte is to
divide the difference in the migration distance (x) by the average peak width (w) , as seen
in:

R = 2 (x2-x1)/(w1+w2)

(1-2)

In the case of capillary separations, x would be determined by the electrophoretic
mobility of the analyte, while w would be determined by the amount of band broadening
during separation. If we redefine resolution in terms of a Gaussian distribution

R = ∆xi/4σ (1-3)

The two peaks touch at the baseline when ∆x = 4σ and R=1. We can further use variance
(σ) for the definition of theoretical plate count where

N = L2/σ2 (1-4)

and the height equivalent of a theoretical plate, or HETP is

HETP = L/N = σ2tot/L (1-5)
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These equations describe the efficiency of the separation, is a description of the analyte
peak shape, and is a useful concept to relate factors of the analytical separation method. It
is important to note that the total variance of the separation is due to a number of
dispersive factors and can be rewritten as:

σ2tot = σ2diff + σ2T + σ2int + σ2wall + σ2other (1-6)

These sources of variance include variances due to analyte diffusion (σ2diff) within
the capillary, variance due to temperature (σ2T) due to heating as a result of current
passing through the capillary, variances due to the injection of sample into the capillary
(σ2int), variances due to interactions of the analyte with the capillary wall (σ2wall) and
other variances (σ2other). These other variances may include specific or nonspecific
interactions of the analyte, such as interactions of the glycans to lectins or enzymes. This
is further discussed in Chapters 3 and 4. Variances due to the injection of sample into the
capillary will be discussed in Chapter 2.
Increasing the migration distance the analytes must travel has been shown to
increase analyte resolution. This can be accomplished by increasing the effective
capillary length [9,10]. This effect is determined from Giddings [11] which expresses the
resolution as:

Rs = ( N1/2 / 4)(∆υ/ῡ)

(1-7)
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where N is the number of theoretical plates, and (∆υ/ῡ) is the relative velocity difference
between two analytes. This states that resolution can be related to theoretical plate count.
Jorgenson and Lukas [6] further describe this relationship by stating that, if band
broadening in CZE can be attributed only to molecular diffusion longitudinally, the plate
count can be given as:

N = l2/2Dt

(1-8)

where D is the diffusion coefficient of the analyte, l is the effective length of the
separation, and t is the migration time of the analyte through the effective length. This
means that a method of improving separation efficiency is to increase the length of the
separation. This effect is further explored in Chapter 2.

1.2 Phospholipid Separations

Because the electrophoretic mobility of an analyte is proportional to the viscosity
of the separations media, higher viscosities will result in longer separation times and
better resolved analytes. Solutions of phospholipids known as bilayered micelles, or
bicelles, are known to have changeable viscosities that are dependent on temperature.
These phospholipids can be easily introduced into the capillary and provide superior
resolution and separation efficiencies in CE separations. The phospholipid preparations
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of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-snglycero-3-phosphocholine (DHPC) used as a separations media in this research undergo
various morphologies, and thus viscosities. These morphologies are bilayered micelles
(bicelles), ribbon-like micelles, and transient interconnected bilayer networks shown in
Figure 1-3 [12-14].

DHPC

A

DMPC

C

D
B

Monday, October 10, 2011

Figure 1-3 shows the phospholipids of study, and their supramolecular morphologies.
Figure 3-A shows the two phosphocholine phospholipids used for these studies, short
chained DHPC and long chained DMPC. Also shown are the morphologies of these
lipid preparations: free floating bicelle discs, long chained ribbons, and entangled
ribbons, Figure 3-B, 3-C, and 3-D respectively. Figure adapted from [12].

Bicelles are disk-like structures with a circular center of bilayered DMPC capped
with a rim of DHPC (Figure 1-3-B). The radius of this disc is dependent on temperature,
hydration, and q value, or the concentration ratio of DMPC to DHPC. This is the primary
11

structure of bicelle preparations at room temperature. At higher temperatures (~24 ℃) the
morphology of the bicelle transitions from disc bicelles to a ribbon-like micelle (Figure
1-3-C) [12]. This morphology results in an substantial increase in viscosity. As the
temperature increases these ribbons become more entangled, and result in a further
increase in viscosity (Figure 1-3-D). This phospholipid material makes an excellent
additive for capillary electrophoresis, as it can be easily introduced into the capillary at
low temperatures unlike the highly viscous linear polymer additives used in capillary gel
electrophoresis.

1.2.1 Phospholipid Separations

Phospholipids have been used in a number of capillary-based separations
techniques. Phospholipid preparations have been used as a coating in CE to suppress the
electroosmotic flow and to prevent nonspecific adsorption to the capillary walls [15-18].
They have also been polymerized to immobilize proteins in capillaries and microfluidics
for affinity targeting [19,20] , and have been used as a pseudo-stationary phase [21,22].

It is important to note that separations of glycans in phospholipid media are not
due to sieving. Sieving is a common separation scheme for biopolymers such as the case
of separation DNA molecules based on size [23]. Plotting the logarithm of velocity vs the
logarithm of molecular mass of homologous series (Ferguson plot) and comparison the
resulting slope provides information the mode of separation. Separation of glycans (linear
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or branched) were found to have same slope below and above the entanglement
thresholds for the gel in use, indicating that glycans separated by capillary

gel

electrophoresis separate strictly on differences in charge to size ratio [24]. The same
experiment was accomplished with glycan separations in phospholipid media. The data
fit for glycans separated in phospholipid media was linear (R2 = 0.998) with slopes of
(-0.620) that were the same above and below the entanglement threshold of the polymer
[5]. This indicates that glycans in phospholipids also are separated based on their
hydrodynamic volumes through a viscous media, and not through a mechanism of
sieving.

1.3 Oligosaccharide analysis

The analysis of carbohydrates provide unique challenges to separations scientists.
Glycans affect numerous crucial biological processes and are the molecule of interest in
many biochemical studies. While oligosaccharides tend to be similar in overall chemical
composition, they display highly complex structures as a result of variable linkage,
position, and type.

Therefore glycans make excellent test molecules to assay the

efficiency and resolution of a separations technique such as capillary electrophoresis.

13

1.3.1 Glycans
Carbohydrates are among the most abundant of biological molecules, and affect
numerous aspects of cellular development and biochemistry. Cellular glycosylation is
essential for cell-to-cell communication and internal cellular communication. Glycans
affect the folding of proteins as a post-translational modification, as well as the solubility,
antigenicity, and eventual clearance of the protein from the body [25]. Glycans derived
from glycoproteins are either N- (asparagine), or O- (serine/threonine) linked to the
polypeptide sequence of the protein.

The focus of this body of work is on N-liked

glycans. Oligosaccharides are comprised of multiple glycan monomers, and monomers
common to N-linked glycosylation include N-acetylglucosamine (GlcNAc), galactose
(Gal), glucose (Glc), mannose (man), fucose (Fuc), and N-acetylneuraminic acid
(NeuAc) (structures shown in Figure 1-4).
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Figure 1-4 shows glycan monomers typical to N-type glycosylation.

N-glycans all contain a di-GlcNAc, tri-Man core that is attached to the protein.
Oligosaccharides can be connected through variable monomer linkage positions and
types (α or β) but fall into common overall structure types (Figure 1-5). The overall
structures of N-linked glycans can be broken into 3 broad types. These include complex
type glycans, high mannose glycans, and hybrid glycans that combine characteristics of
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the two. These structures can be further modified through bisecting GlcNAc monomers,
and the addition of fucose.

high mannose type
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3

complex type

1
and

Fuc

GlcNAc

Man

Gal

1
2
Neu5Ac

hybrid type
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Figure 1-5 shows examples of high mannose, complex, and hybrid type glycans. Also
shown is a key describing the various glycan monomers and linkages described in the
text.

Both simple and complex carbohydrates tend to be similar in structures,
consisting primarily of polyhydroxylated hydrocarbons that are usually very polar and
nonvolatile. While carbohydrates display highly similar structures in chemical structure,
the overall complexity can be extensive. This is demonstrated in the comparison of of
glycan linkages to amino acid linkages. For example, while 2 identical amino acids link
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into a single dipeptide, 2 identical glucose molecules can form 11 different disacchardies.
Four different hexopyranoses can produce more than 36,000 different tetrasaccharides
[26]. Issues of linkage, position, and type result in great complexity of the final glycan
structure.

1.3.2 Derivatization of Glycans for CE separations

A challenge to analyze oligosaccharides is that they are not easily detected
through optical methods. Carbohydrates are not naturally chromophoric or fluorophoric
and thus are not amenable to detection with UV-absorbance or laser-induced
fluorescence. Additionally, glycans, which naturally contain charge only through in
inclusion of sialic acid, are neutral. Labeling the glycan with a fluorescent tag often
serves to provide charge to the molecule, and thus a method of electrophoretic migration
through the capillary. A variety of derivatization reagents have been reported by the
fluorescence detection of mono- and oligosaccharides in CE, and include labels such as
3- (4-carboxybenzoyl)-2-quinolinecarboxaldehyde (CBQCA) [27] , 8aminonaphthalene-1,3,6-trisulfonic acid (ANTS) [28], and 1-aminopyrene-3,6,8trisulfonic acid (APTS) [29]. The use of APTS for the derivatization of glycans has been
well documented and is the label used for this research.
The labeling strategy for APTS is shown in Figure 1-6. The amine group from
APTS attaches to the anomeric carbon of the sugar to form a reversible Schiff base. This
bond attaches through reductive amination, and is further reduced to a stable bond with
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the incorporation of sodium cyanoborohydride. The APTS provides three additional
negative charges to the glycan molecule. The labeling of APTS occurs in a 1:1 fashion
with the sugar, proving a constant application of charge and label, and allowing for the
development of quantitative analysis and for the separation of the glycan based on
charge.
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Figure 1-6 displays the reaction scheme for the derivatization of carbohydrates with
APTS.
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Chapter 2

Development of Phospholipid Assisted CE for Efficient
Glycan Separations
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2.1 Introduction
The separations of glycans using phospholipid additives in capillary
electrophoresis was first reported by Luo et al in 2010 [1]. In this application,
phospholipids served to suppress the electroosmotic flow and acted as a viscous
separation media to improve analyte resolution and efficiency. This chapter covers the
advancement of phospholipid separations in terms of injection optimization, capillary
inner diameter, capillary length, and field strength.

2.1.1 Phospholipids
Phospholipids have been utilized to enhance chemical separations for studies of
membrane affinity [2], lipophilicity [3], and liposome interaction [4], and as a
pseudostationary phase to separation proteins [5]. Phospholipids are excellent coatings
for capillary electrophoresis, as they are naturally biocompatable, and form semipermanent coatings that do not require covalent modification of the capillary, nor the
presence of the phospholipid in the running buffer. The phospholipids used for the
separation of glycans consist of the long chain phosphocholine 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine
(DHPC) shown in Figure 2-1.
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1,2-dimyristoyl-sn-glycero-3-phosphocholine
DMPC

1,2-dihexanoyl-sn-glycero-3-phosphocholine
DHPC
Figure 2-1 displays the chemical structures of DMPC and DHPC, the two
phospholipids used for this body of work.

Aqueous preparations of these two phospholipids are described in terms of molar
ratios of [DMPC]/[DHPC], or the q value of the solution. Aqueous phospholipid
preparations comprised of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and
1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) display atypical temperaturedependent viscosity. At temperatures below the gel phase transition, the viscosity of an
aqueous phospholipid preparation is similar to that of water. Above the gel phase
transition, the viscosity increases dramatically to a maximum at ∼29 °C. [6] The
temperature-induced change in viscosity of aqueous phospholipid preparations is a
function of the q-value as well as the percent hydration. The viscosity can increase with
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temperature as much as 370-fold for q = 2.5-10% phospholipid preparations and even
more so when comparing preparations of different q-values [6]. This transition has
practical use for capillary electrophoresis separations, as they are easily introduced into
the capillary at low temperatures as an additive for chemical separations.

2.1.2 Effects of Phospholipid Composition on Separations Performance
To appropriately utilize phopsholipid bicelles for the separations of small
molecules such as glycans, a number of parameters were characterized by Luo et al [1].
Because the morphology of the phospholipid affects its overall properties as a separations
media, the effects of lipid content, composition, and temperature on the the separation
were determined. The previous research in this field provided a starting point to this body
of research.

2.1.3 Utilization of Bicelle Coatings and Separations Media
The method of sample introduction for phospholipid-mediated capillary
electrophoresis separations must account for a significant temperature dependent change
in viscosity of the media. Therefore, the filling of the capillary, and other hydrodynamic
injections are performed for phospholipid preparations of different viscosity by injecting
samples at temperatures below the gel-phase transition at which all phospholipid
preparations display similar low viscosity. Following the injection, the capillary
temperature is increased to a specified value and the separation proceeds. This protocol

27

can increase the total analysis time by as much as 5 min but is necessary to compare
open-tubular separations with phospholipid-mediated separations.

2.1.4 Effects of Q-value, Hydration and Temperature
Previous research compared three different ratios of [DMPC]/[DHPC], or qvalues. Q-values of q = 1.5, 2.0, and 2.5 were compared at equivalent percent hydration
(5%). Separations of branched glycans were conducted using these three solutions at
various temperatures ranging from 21 to 35 ℃. The migration reproducibility varied with
the q value, with q values of 2.5 providing the best reproducibility. While there was no
discernible trend in the theoretical plate count or resolution of glycans with these three
5%, phospholipid preparations, q = 2.5 phospholipid preparations were used to provide
the reproducibilities needed for more precise analysis.
Q = 2.5 phospholipids at 5, 10, and 15% preparations were also compared at
various temperatures (21 to 35℃) in terms of separation efficiency and resolution. Q 2.5,
10% preparations provided overall better separations than the other two percent
hydrations. A separation of the branched glycans taken from bovine asialofetuin showed
that, for a 40.2 cm capillary (30.2 cm effective length) with a 50 µm i.d, theoretical plate
counts as high as 240,000 could be obtained. These maximum efficiencies, and the
maximum resolutions were obtained at 25 ℃. Therefore this report utilized phospholipid
additives that were q = 2.5, 5% hydration and were used for separations at 25 ℃, and
were also used for the studies in this body of work.
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2.1.5 Sample Introduction
The method of sample introduction a the capillary must account for the significant
change in viscosity following change in temperature to the phospholipid separations
media. This viscosity can result in inconsistent injections if a suitable protocol for the
electrokinetic introduction of sample into the capillary is not used. Luo et al first reported
the use of a small aqueous plug of buffer into the phospholipid before and after the
electrokinetic injection of the glycan [1]. Electrokinetic sample introduction is also
frequently employed in capillary gel electrophoresis, where a small aqueous plug is
hydrodynamically injected into the capillary before electrokinetically injecting the
analyte. Inclusion of this pre-plug was shown to improve sample introduction [1,7]. A
small plug of buffer following the electrokinetic injection was also shown to reduce peak
tailing [8] and thus was also incorporated .The protocol utilizes an aqueous pre-plug of
MOPS into the phospholipid material before and after the analyte is electrokinetically
injected. These pre and post plugs improve the reproducibility of peak area and greatly
reduces peak asymmetry.
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2.2 Experimental
2.2.1 Chemicals and Materials

Reagents were obtained from a variety of manufacturers. Sigma Aldrich (St. Louis, MO,
USA) was the source for asialofetuin from fetal calf serum, 3-(N-morpholino)propanesulfonic acid (MOPS), calcium chloride dihydrate, maltooligosaccharide
standards, sodium chloride, and sodium hydroxide. Methanol and α1-acid glycoprotein
(AGP) were purchased from EMD Biosciences (La Jolla, CA). Ethanol was obtained
from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) were obtained from
Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8-trisulfonic acid (APTS) was
purchased from Biotium (Hayward, CA). Sodium cyanoborohydride (NaCNBH3) was
acquired from Strem Chemicals (Newburyport, MA). Triethylamine, acetonitrile, and
citric acid were acquired from Fisher Scientific (Pittsburgh, PA). An Elga Purelab ultra
water system (Lowell, MA) was used to provide deionized water.

2.2.3 Glycan Labeling and Preparation

Glycans derived from glycoproteins (Rnase B, asialofetuin, and α-acid glycoprotein)
were prepared as follows. Glycans were removed from protein sources using a PNGase F
kit using protocol based on the kit from the manufacturer. Briefly the protein is denatured
using a solution containing sodium dodecyl sulfate (SDS), dithiothreitol (DTT) and
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heating at 95 ℃ for 10 minutes. The nonionic surfactant NP-40 is then added to the
solution to prevent the DTT from denaturing the enzyme PNGase F, which immediately
added afterward. This reaction was incubated at 37 ℃ overnight, rather than the 2 hours
suggested by the protocol. The next day, a 3X volume of ice-cold ethanol was added to
precipitate the protein. The solution was centrifuged at 4 ℃ at 10 000 rpm for 10
minutes. The liquid fraction containing cleaved glycans was dried using a Savant
SpeedVac concentrator (ThermoScientific, Waltham, MA). The dried glycans , or dried
glycan standards were reconstituted in 1µL of a 0.2 M solution of APTS dissolved in 1.2
M citric acid, along with 1µL of 1 M NaCNBH3 in deionized water. The solution was
thoroughly mixed before being incubated overnight at 37 ℃. The reaction was stopped
with the addition of 100 µL of deionized water. If needed, the sialic acid was removed by
adjusting the pH of the glycan solution to 6 with sodium hydroxide then incubating it
overnight with neuraminidase. If necessary, a 10 kDa molecular weight cut off filter
(Sartiorius, Stonehouse, UK) was used to remove the neuraminidase followed by removal
of excess APTS by a Discovery DPA-6S solid phase extraction cartridge (50 mg packing,
Supelco, Bellefonte, PA). A flush of 95:5 (v/v) acetonitrile:water was used to prepare the
cartridge prior to use. APTS was eluted from the extraction cartridge with a solution
containing 95:5 (v/v) acetonitrile:water containing 50mM trimethylamine. An aqueous
solution of 50mM triethylamine was used to elute the retained glycans from the cartridge.
The glycan solution was evaporated to dryness and the reconstituted in 100 µL deionized
water and stored at -20 ℃.
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2.2.4 Phospholipid Preparation

Preparations of phospholipids were comprised of 5%, [DMPC]/[DHPC] (q value) = 0.5
were used for coating of the capillary, which serves to suppress the electroosmotic flow,
and to passivate the surface from nonspecific interactions. Another phospholipid
preparation of a 10%, q= 2.5, phospholipid solution was used for the separation media,
due to the thermally-switchable gel-like viscosity of the material. These phospholipids
were prepared by weighing out the appropriate masses of dry DMPC and DHPC, then
adding 100 mM aqueous MOPS buffered to pH 7. After the solution was thoroughly
mixed, the preparation was subjected to a minimum of three freeze-thaw cycles and
centrifuged for 10,000 rpm for ten minutes. The phospholipid preparation was stored at
-20 ℃, and was thawed and vacuum degassed prior to use.

2.2.5 Capillary Electrophoresis

Separations were performed using a P/ACE MDQ Capillary electrophoresis
system (Beckman Coulter, Fullerton, CA) equipped with laser induced fluorescence
detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The fused silica
separation capillary had a 25 µm internal diameter and a 360 µm outer diameter
(Polymicro Technologies, Phoenix, AZ) with an effective length of 50.0 cm and a total
length of 60.2 cm. Capillaries were subject to the following flushing sequence daily: 1 M
NaOH for 30 minutes at 170 kPa (25 psi), deionized water for 15 minutes at 170 kPa (25
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psi), methanol for 15 minutes at 170 kPa (25 psi), and 15 minutes of water at 170 kPa (25
psi). Following this flushing sequence, the capillary was passivated with a phospholipid
coating with a 5%, q = 0.5 phospholipid preparation containing 1.25 mM calcium. This
semi-permanent coating was applied for 20 minutes at 170 kPa (25 psi) followed by a 2
minute MOPS flush at 170 kPa (25 psi) to remove excess phospholipid and from the
capillary. A brief pre-coat was applied prior to each run using the following protocol at
170 kPa (25 psi) with the capillary held at 19℃: q = 0.5, 5% phospholipids for 3 minutes,
MOPS for 2 minutes, and q = 2.5, 10% phospholipids for 3 minutes. If enzyme was being
used in-capillary, an additional 3 minute 170 kPa (25 psi) MOPS flush was performed in
the reverse direction before this sequence, to expel any enzymes from the capillary, and
to prevent fouling of the capillary. When the room temperature was higher than 22 ℃, a
portable air conditioner was used to provide ambient thermal control. Injections into the
capillary were carried out in three steps. First, a plug a MOPS was injected into the
phospholipid filled capillary (7 sec, at 6.9 kPa) at 19 ℃. The capillary temperature was
then heated to 25 ℃, resulting in the viscosity of the q = 2.5 10 % phospholipid filling to
increase to a gel-like consistency. The glycan is then electrokinetically injected into the
capillary. Finally a post-plug of MOPS was pressure injected (5 sec, 3 kPa). Separations
were carried out at 400 V/cm under reversed polarity. Data collection and analysis were
performed using 32 Karat Software version 5.0 (Beckman Coulter). Theoretical plates
were calculated using 32 Karat Software using the “USP plates” criterion.
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2.3 Results and Discussion
The results provided in this section have been peer-reviewed and published in reference
[9].

2.3.1 Effects of Capillary Inner Diameter
Previous experiments utilizing phospholipid additives were accomplished with a
50 µm i.d., 30.2 cm effective length capillary [1], but should be compatible with varying
capillary inner diameters, including 25 µm i.d.s. The advantages of utilizing a smaller
i.d. capillary include reduced consumption of phospholipid additives as well as
incorporated proteins. This advantage is explained further in Chapters 3 and 4 of this
document. Reducing the i.d. of the capillary also results in a reduction of the separation
current. The majority of separations reported in this research were accomplished in a 25
µm inner diameter. While separations with 75 and 100 µm i.d capillaries are feasible, they
were not pursued.

2.3.2 Optimization of Injection
This protocol utilizes an aqueous pre-plug of MOPS into the phospholipid
material before and after the analyte is electrokinetically injected.

The protocol was

originally reported by Luo et al. [1] for a 50 µm i.d., 30.2 cm effective length capillary,
but was further optimized for a 25 µm i.d capillary. Experiments were conducted to
determine optimum pre and post-plug sizes, as well as the effects of injection size on
separation efficiency and area reproducibility.
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The injection of a small plug of buffer prior to the electrokinetic injection of
sample creates an ion depleted zone for the negatively charged glycans to inject into [7].
To determine if the volume of the buffer pre plug affects the plate count, two different
plug sizes were compared for a 10 kV 3 sec injection of high mannose glycans from
RNase B in a 30.2 cm capillary. The results of these separations are shown in Table 2-2.
They reveal no statistical difference until the plug size was less than 3 kPa (0.5 psi) 7 sec.
Under these conditions the oligosaccharides could no longer be reproducibly injected.
Therefore injections were accomplished with a 6.9 kPa (1psi) 7 sec, unless otherwise
noted.

Table 2-1: Comparison of Pre-plug Size
Plug size
10psi 7 sec
1psi 7 sec
0.5psi 5 sec

Plates
370,000
420,000
370,000

Area
4600
4300
4800

Mannose 6 (from Rnase B), n = 1, Leff = 40.2cm, Lt =
50.2cm, sample injected for 10kV 3 sec, Eapp = 400 V/cm,
BGE=100mM MOPS pH 7. This data was reproduced with
permission from [9]. Copyright 2011 American Chemical
Society.

Table 2-2: Comparison of Two Pre plug Sizes
Plug size
Time (RSD%) Area (RSD%) Plates (RSD%)
3 kPa (0.5psi) 7 sec 6.95 (1%)
92,000 (20%) 78,000 (4%)
6.9 kPa (1psi) 7 sec 6.85 (1%)
91,000 (20%) 81,000 (5%)
Mannose 6 (from RNase B), n = 3, Leff = 20.2 cm, Lt = 30.2 cm, sample injected for
10kV 3 sec, Eapp = 400 V/cm, BGE=100mM MOPS pH 7. Time is in minutes. This
data was reproduced with permission from [9]. Copyright 2011 American Chemical
Society.
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The injection of a small plug of MOPS after the electrokinetic injection in the 50
µm i.d. capillary prevents peak tailing [1], as a result of carryover of analyte [8]. No
statistical difference in area or plate count was obtained with the inclusion of a postinjection plug (as shown in Table 2-3). However, because the inclusion of a small postinjection plug did not increase the analysis time, and does prevent long-term
contamination of the separation buffer vials, a (3 kPa (0.5psi) 5 sec) plug was used.

Table 2-3. Effect of Post plug size
Post Plug
wait
0.5psi 5s + wait
1psi 7s + wait
5psi 5s + wait

Time (RSD)
13.2 (1%)
13.1 (1%)
13.1 (1%)
13.1 (1%)

Area (RSD)
49,000 (20%)
43,000 (7%)
44,000 (20%)
45,000 (20%)

Plates (N)
520,000 (4%)
520,000 (2%)
530,000 (3%)
530,000 (5%)

Mal 5 (from Maltoses), n = 3, Leff = 50.2cm, Lt = 60.2cm, sample injected for 10kV 3
sec, Eapp = 400 V/cm, BGE=100mM MOPS pH 7. This data was reproduced with
permission from [9]. Copyright 2011 American Chemical Society.

The time of the electrokinetic injection affects separation efficiency, as the peak
broadening associated with sample introduction is related to the analyte injection band
size [10-12]. Therefore, the highest efficiency separations are obtained with the smallest
possible injection volumes. However, the ramp time for applied voltage affects the peak
area reproducibility. This is demonstrated in Table 2-4 using the glycans derived the
RNase B, which compares three injections of varying injection voltage but identical
duration. As the injection voltage is increased, the width of injection band increases. This
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reduces the plate count, as the area increases. The highest plate count was obtained for a
2 kV 9 sec injection. However, the area reproducibility of injections performed at 2 kV 9
sec had a relative standard deviation of 20 %.

Table 2-4. Effect of injection Size on Area Reproducibility
Injection
2kV 9 sec
4kV 9 sec
6kV 9 sec

Area (RSD)
34,000 (20%)
89,000 (5%)
133,000 (5%)

Plates (N)
97,000 (3%)
76,000 (5%)
48,000 (3%)

Mannose 6 (from RNase B), n = 5, Leff = 20.2cm, Lt = 30.2cm, other
conditions as described in Table 1. This data was reproduced with
permission from [9]. Copyright 2011 American Chemical Society.

The trade-off between precision and plate count is further demonstrated in Table
2-5. If the user requires highly efficient separations, an injection of 10 kV 3 sec may be
used. However, if quantitative data is required, a 4 kV 5 sec injection will result in a
reduced plate count, but area reproducibilities of 6 %.

Table 2-5. Effect of Injection Size on Precision and Plate Count
Injection
10kV 3 sec
4kV 5 sec

Time (RSD)
15.1 (0.1%)
14.7 (1%)

Area(RSD)
16,000 (10%)
28,000 (6%)

Plates (N)
537,000 (2%)
485,000 (6%)

Mannose 6 (from RNase B), n = 5, Leff = 50.2 cm, Lt = 60.2 cm, Eapp = 400 V/cm,
anodic/cathodic reservoir contain 100 mM MOPS buffered at pH = 7, capillary filled
with 10% q = 2.5 phospholipid as described in the text. This data was reproduced with
permission from [9]. Copyright 2011 American Chemical Society.
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2.3.3 Effects of Capillary Length on Efficiency
To characterize the effects of capillary length on the separation efficiency,
branched glycans taken from RNase B (Table 2-6) and linear maltooligosaccharides
(Table 2-7) were separated in capillaries with varying effective lengths. The total
capillary length varied from 30.2 to 60.2 cm, which the effective capillary length varying
from 10.2 to 50 cm. Separations of the glycans were injected for 10 kV 3 sec and
separated at an applied voltage of 400 V/cm. When the effective capillary length was
increased, the corresponding plate count also increased. This trend was equivalent for
both the branched and linear glycans. When the total length of the capillary was kept
constant, but the effective length was changed, the higher effective separation length
resulted in a higher theoretical plate count. This was accomplished by performing
separations on a capillary with a total length of 60.2 cm, but introducing sample from
either end of the capillary, providing an effective length of either 10.2 or 50.0 cm.
Interestingly, the gains in efficiency as a function of increasing effective length are not
linear. This can be seen in both Tables 2-6 and 2-7 where the plates per meter also
increase with increasing effective capillary length. Based on this data, the optimum
separation length was determined to be with a 50.0 effective, 60.2 cm total capillary
length, which provided theoretical plate counts of more than a half a million plates
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Table 6. Effect of Length on Separation Efficiency
Leff (cm)
10
20
30
40
50

Time (RSD)
3.11 (1%)
6.05 (0.2%)
8.88 (0.7%)
12.14 (0.4%)
15.1 (0.1%)

Plates (RSD)
Plates per meter (N/m)
32,000 (3%)
320,000
133,000 (2%)
665,000
234,000 (3%)
780,000
378,000 (1%)
945,000
530,000 (2%)
1,060,000

Mannose 6 (from RNase B), n = 5, sample injected for 10kV 3 sec. The applied
voltage was 400 V/cm. The anodic/cathodic reservoir contained 100 mM MOPS
buffered at pH = 7, and the capillary was filled with 10% q = 2.5 phospholipid as
described in the text. RSD = relative standard deviation. This data was reproduced
with permission from [9]. Copyright 2011 American Chemical Society.

Table 7. Effect of Length on Separation Efficiency (linear glycan)
Leff (cm) Time (RSD)
10
2.74 (0.7%)
20
5.41 (0.2%)
30
7.85 (0.1%)
40
10.75 (0.01%)
50
13.38 (0.2%)

Plates (N)
Plates per meter (N/m)
44,000 (5%)
440,000
149,000 (1%)
745,000
247,000 (2%)
823,000
370,000 (3%)
930,000
536,000 (1%)
1,070,000

Maltose 5 (from linear maltoses), n = 5, sample injected for 10kV 3 sec. The
applied voltage was 400 V/cm. The anodic/cathodic reservoir contained 100 mM
MOPS buffered at pH = 7, and the capillary was filled with 10% q = 2.5
phospholipid as described in the text. RSD = relative standard deviation. This
data was reproduced with permission from [9]. Copyright 2011 American Chemical
Society.

2.3.4 Effects of Electric Field Strength on Efficiency
Separation efficiency is increased in CE when the applied voltage is as high as
possible without inducing band broadening due to Joule heating. The risk of Joule heating
is especially relevant to the use of phospholipid additives due to the temperature
dependent viscosity of the media. Therefore, the highest applied field strength that does
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not lead to Joule heating will provide the best efficiency. Because the maximum applied
voltage for the Beckman P/ACE MDQ capillary electrophoresis instrumentation is
limited to 30 kV, a shorter capillary (40.2 cm, 25 µm) was utilized to provide a wide
range of field strengths. A plot of plate height versus the electric field strength is shown
in Figure 2-2. The field strengths range from 100 to 600 V/cm. and were based on the
n=3 separation efficiencies of maltopentaose. The lowest plate heights were obtained at
field strengths between 350 V/cm and 450 V/cm. This information is consistent with the
separation suffering from longitudinal band broadening at field strengths at field
strengths below 350V/cm , and Joule heating effects at field strengths above 450 V/cm.
Therefore all glycan separations were performed at an effective field strength of 400 V/
cm.
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Figure 2-2 displays a plot of separation efficiency as a function of applied electric field.
Each plotted data point is determined from three electrophoretic separations of
maltopentaose. This data was reproduced with permission from [9]. Copyright 2011 American
Chemical Society.
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2.3.5 Limits of Detection
The limit of detection of this method was estimated for a 10kV 3 sec injection
using the linear maltooligosaccharide, maltopentaose. This oligosaccharide was labeled
with APTS as the limiting reagent. Assuming the labeling efficiency was 100%, a 300
femtomolar sample of maltopenaose was electrokinetically injected to the separation
capillary. This separation yielded a signal to noise (S/N) ratio of 60, and thus a limit of
detection of 15 femtomolar.

2.4 Conclusions
This chapter demonstrates the further development of efficient separations for
capillary electrophoresis with phospholipid-additives. These separations are
accomplished without any covalent modification of the capillary, and can be
accomplished in a variety of capillary inner diameters. This i.d. compatibility is critical
because modified capillaries smaller than 50 µm i.d. are not easily obtained
commercially. As a 25 µm i.d. provided a reduction in reagent consumption and
separation current, it was chosen for continued studies of . The highest separations
efficiencies were obtained in capillaries with the longest effective separation length.
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Chapter 3

Optimization of In-Capillary Interactions of Glycans to
Lectins and Enzymes
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3.1 Introduction

Carbohydrates are vital to cellular biological processes where they play key roles
such as cell-cell recognition, cell-matrix recognition, and cellular regulation [1].
However, the determination of the structural characteristics of glycoproteins is nontrivial,
due in part because of the wide variability of glycosylation and the prevalence of
isomeration. Additionally, a small changes in the glycan structure can significantly
influence the biological activity of the glycoprotein. This is especially true for
glycoproteins manufactured for therapeutic purposes, where changes in glycosylation
may dramatically affect the overall pharmacological efficacy of the glycoprotein.
Carbohydrate-specific proteins such as lectins and exoglycosidase enzymes have been
shown to be effective methods of oligosaccharide characterization. By incorporating
these proteins into the separations capillary, glycans introduced into it with the targeted
structural features will be bound or enzymatically cleaved. This results in changes to the
electropherogram by removing (for lectins) or shifting (for enzymes) the peak.

This

chapter describes a means to incorporate lectins and enzymes into a phospholipid-filled
capillary to rapidly characterize and sequence glycan samples. The work described in this
chapter has been published in [2][3].
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3.1.1 Lectins

Lectins are plant and animal isolated proteins that bind to carbohydrates with high
affinity. Lectins are of non-immune origin and have no catalytic activity and thus are
unique from antibodies and enzymes in this regard [4]. The cellular functionalities of
lectins vary and have been implicated in cellular recognition [5], the recognition of
cellular hosts by viruses [6], cell growth and differentiation [7], as well as number of
other functions.

The highly specific nature of lectins for a particular glycan

characteristic, makes it useful for a number of biochemical applications. These
applications include blood typing, glycan analysis, preparative scale isolation of
glycoconjugates, as well as studies that focus on cellular agglutination and cellular
separation and identification. The binding affinities of lectins (102 - 106 M-1) are not as
strong as that of carbohydrate-binding antibodies (104 - 108 M-1), which provides a
distinct advantage [8]. Unlike immunoaffinity interactions that may require harsh
conditions to trigger release after binding, the conditions for release of a glycoconjugate
from a lectin is comparatively mild, allowing for the release of intact glycoprotein or
whole cell.

Lectins are commercially available, and are produced from a number of

naturally derived sources.
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3.1.2 Mass Spectrometry

Mass spectrometry is a powerful tool that has been extensively used in the study
of glycans and glycoconjugates, and providing a basis for the structural characterization
of the glycan structure. Both matrix-assisted laser desorption/ionization (MALDI) and
electrospray ionization offer unique advantages for the analysis of glycans [9]. However,
determining glycan sequence with each method also has number of challenges. These
include difficulties in elucidating the correct linkage of residues, and an inability to
distinguish isomers. As a result, interpretation of these spectra often must be overcome
with complicated analyses, often by requiring sophisticated computational methods of
bond linkage determination [10,11]. Challenges in ionization and detection are often due
to the presence of additional negative charges, such as through the addition of sialyated
species [12]. To provide better ionization for MS analysis, they must be derivatized
through methods such as permethylation prior to analysis. The method of ionization can
result in increased spectra complexity. Electrospray ionization spectra often are
complicated by the appearance of different charge states, ion suppression, and adduct
formations, while MALDI ionization requires derivatization prior to analysis to prevent
fragmentation, and to facilitate quantitative analysis [13]. Due to the complexity of most
biological glycan samples, both methods often require analytical separations prior to
ionization and analysis. While ESI methods can be readily coupled online to chemical
separations methods such as CE and HPLC, MALDI methods must be coupled off-line.
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The difficulties in determining linkage, and in distinguishing between isobaric
glycan isoforms have led to the enzymatic cleavage of these glycans prior to analysis.
Mass spectrometry sequencing following enzymatic treatment has been utilized for both
ESI coupled to ion trap [14,15] and MALDI coupled to time-of-flight mass analysis [16].

3.1.3 Exoglycosidase Enzymes

Exoglycosidase enzymes are glycosidic hydrolase enzymes that selectively cleave
the terminal residues of glycans. In addition to monomer specificity, these enzymes can
also be both position and linkage specific. Exoglycosidases are readily available through
a number of commercial sources. While the use of these enzymes for benchtop analyses
have been well documented, these reactions face a number of obstacles. The incubation
times required for glycan hydrolysis in free solution can be lengthy, and the amounts of
glycan and enzyme required per analysis can be cost prohibitive. Reaction products must
be analytically separated from the unreacted original substrate. Furthermore, errors
related to sample handling can affect the overall performance of the final method.
Therefore ideal methods that utilize exoglycosidases for glycan analysis should use low
amounts of glycan and enzymes, be low volume, and should be integrated into the
methods of separation to provide reduced sample handling and losses due to sample
transfer.

49

3.2 Experimental

3.2.1 Chemicals and Materials:
Reagents were obtained from a variety of manufacturers. Sigma Aldrich (St.
Louis, MO, USA) was the source for asialofetuin from fetal calf serum, 3-(Nmorpholino)-propanesulfonic acid (MOPS), calcium chloride dihydrate,
maltooligosaccharide standards, sodium chloride, and sodium hydroxide. Methanol and
α1-acid glycoprotein (AGP) were purchased from EMD Biosciences (La Jolla, CA).
Ethanol was obtained from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine
(DHPC) were obtained from Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8trisulfonic acid (APTS) was purchased from Biotium (Hayward, CA). Sodium
cyanoborohydride (NaCNBH3) was acquired from Strem Chemicals (Newburyport, MA).
Triethylamine, acetonitrile, and citric acid were acquired from Fisher Scientific
(Pittsburgh, PA). Ribonuclease B (Rnase B), α1-2,3 mannosidase, β1-4 galactosidase,
neuraminiase, β-N-acetylglucosaminidase, and a peptide N-glycosidase (PNGase F) kit,
were obtained from New England Biolabs (Ipswich, MA). A G7 10X reaction solution
composed of 0.5M sodium phosphate buffered at pH 7.5, a glycoprotein denaturing
solution containing 5% sodium dodecyl sulfate (SDS), and 0.4 dithiothreitol (DTT), and
10% solution of nonionic surfactant NP-40 were included in the PNGase F kit. A G1 10X
reaction solution composed of 0.5M sodium citrate buffered at pH 6 was provided in the

50

neuraminidase kit. An Elga Purelab ultra water system (Lowell, MA) was used to provide
deionized water.

3.2.2 Preparation and Derivatization of Glycan Standards
Glycans derived from glycoproteins (Rnase B, asialofetuin, and α-acid
glycoprotein) were prepared as follows. Glycans were removed from protein sources
using a PNGase F kit using a protocol based on the kit from the manufacturer. Briefly the
protein is denatured using a solution containing SDS and DTT and heating at 95℃ for 10
minutes. The nonionic surfactant NP-40 is then added to the solution to prevent the DTT
from denaturing the enzyme PNGase F, which immediately added afterward. This
reaction was incubated at 37℃ overnight, rather than the 2 hours suggested by the
protocol. The next day, a 3X volume of ice-cold ethanol was added to precipitate the
protein. The solution was centrifuged at 4℃ at 10 000 rpm for 10 minutes. The liquid
fraction containing cleaved glycans was dried using a Savant SpeedVac concentrator
(ThermoScientific, Waltham, MA). The dried glycans , or dried glycan standards were
reconstituted in 1µL of a 0.2M solution of APTS dissolved in 1.2M citric acid, along
with 1µL of 1 M NaCNBH3 in deionized water. The solution was thoroughly mixed
before being incubated overnight at 37℃. 100µL of deionized water was used to stop the
reaction. If needed, the sialic acid was removed by adjusting the pH of the glycan
solution to 6 with sodium hydroxide then incubating it overnight with neuraminidase. If
necessary, a 10kDa molecular weight cut off filter (Sartiorius, Stonehouse, UK) was used
to remove the neuraminidase followed by removal of excess APTS by a Discovery
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DPA-6S solid phase extraction cartridge (50mg packing, Supelco, Bellefonte, PA). A
flush of 95:5 (v/v) acetonitrile:water was used to prepare the cartridge prior to use. APTS
was eluted from the extraction cartridge with a solution containing 95:5 (v/v)
acetonitrile:water containing 50mM triethylamine. An aqueous solution of 50mM
triethylamine was used to elute the retained glycans from the cartridge. The glycan
solution was evaporated to dryness and the reconstituted in 100 µL deionized water and
stored at -20℃.

3.2.3 Preparation of Phospholipid Additive
Preparations of phospholipids were comprised of 5%, [DMPC]/[DHPC] (q value)
= 0.5 were used for coating of the capillary, which serves to suppress the electroosmotic
flow, and to passivate the surface from nonspecific interactions. Another phospholipid
preparation of a 10%, q= 2.5, phospholipid solution was used for the separation media,
due to it’s thermally-switchable gel-like viscosity. These phospholipids were prepared by
weighing out the appropriate masses of dry DMPC and DHPC, then adding 100mM
aqueous MOPS buffered to pH 7. After the solution was thoroughly mixed, the
preparation was subjected to a minimum of three freeze-thaw cycles and centrifuged for
10,000 rpm for ten minutes. The phospholipid preparation was stored at -20℃, and was
thawed and vacuum degassed prior to use.
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3.2.4 Capillary Electrophoresis
Separations were performed using a P/ACE MDQ Capillary electrophoresis
system (Beckman Coulter, Fullerton, CA, USA) equipped with laser induced
fluorescence detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The
fused silica separation capillary had a 25 µm internal diameter and a 360 µm outer
diameter (Polymicro Technologies, Phoenix, AZ, USA) with an effective length of 50.0
cm and a total length of 60.2 cm. Capillaries were subject to the following flushing
sequence daily: 1M NaOH for 30 minutes at 170kPa (25 psi), deionized water for 15
minutes at 170kPa (25 psi), methanol for 15 minutes at 170kPa (25 psi), and 15 minutes
of water at 170kPa (25 psi). Following this flushing sequence, the capillary was
passivated with a phospholipid coating with a 5%, q=0.5 phospholipid preparation
containing 1.25mM calcium. This semi-permanent coating was applied for 20 minutes at
170kPa (25 psi) followed by a 2 minute MOPS flush at 170kPa (25psi) to remove excess
phospholipid and from the capillary. A brief pre-coat was applied prior to each run using
the following protocol at 170kPa (25 psi) with the capillary held at 19℃: q=0.5, 5%
phospholipids for 3 minutes, MOPS for 2 minutes, and q=2.5, 10% phospholipids for 3
minutes. If enzyme was being used in-capillary, an additional 3 minute 170 kPa (25 psi)
MOPS flush was performed in the reverse direction before this sequence, to expel any
enzymes from the capillary, and to prevent fouling of the capillary. When the room
temperature was higher than 22℃, a portable air conditioner was used to provide ambient
thermal control. Injections into the capillary were carried out in three steps. First, a plug a
MOPS was injected into the phospholipid filled capillary (7s, at 6.9 kPa) at 19℃. The
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capillary temperature was then heated to 25℃, resulting in the viscosity of the q=2.5
10% phospholipid filling to increase to a gel-like consistency. The glycan is then
electrokinetically injected into the capillary. Finally a post-plug of MOPS was pressure
injected (5 s, 3 kPa). Separations were carried out at 400 V/cm under reversed polarity.
Data collection and analysis were performed using 32 Karat Software version 5.0
(Beckman Coulter).

3.2.5 Enzymatic Reactions
Enzymatic reactions were either conducted in a bench-top reaction, or in capillary.
Benchtop reactions of enzyme were conducted at small volume (<100 µL) in ~0.2 mL
polypropylene tubes in the buffers and conditions suggested by manufacturers. All
incubations, unless otherwise noted, were completed at 37℃ overnight. Enzymatic
reactions completed in-capillary were accomplished by injecting a small plug of the
enzyme solution into the capillary at 19℃, prior to increasing the temperature of the
capillary to 25℃. Glycans were injected into the capillary at this elevated temperature,
and electrokinetically moved at a low voltage into the enzyme plug prior to incubation
and separation, as noted in the text.

3.3 Results and Discussion

The results in this section have been peer reviewed and published in references [2] and
[3].
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3.3.1 Methods of Glycan Identification using Standards
Glycan standards can be used to test the performance of an analytical method.
Standards may also be used to confirm the identity of a glycan of interest. In this work,
both the glycan to be analyzed and the standard glycan are labeled with the fluorescent
tag, APTS. Migration times of the two are then either compared, or the standard is added
to the glycan sample to assign peak composition. Glycan standards can be purchased
commercially, or can be derived from common glycoproteins. Examples of glycoproteins
well-charaterized in literature and thus used as standards are the high mannose glycans
from ribonuclease B (RNase B), as well as the complex-type glycans from bovine serum
fetuin

and α-acid glycoprotein (AGP). Figure 3-1 displays a separation of glycan

standards used in some of the studies completed for this work. These glycans include the
linear maltose oligosacchardies (G4, G5, G6, and G7) that were purchased, glycans
(Man5, Man6, Man7, Man8, Man9) taken from Ribonuclease B, and branched di, tri, and
tetraantennary complex-type glycans from the protein α-acid glycoprotein (AI, AII, AIII,
AIV, and AV). Sialic acid from complex-type glycans was commonly removed prior to
analysis as sialyation drastically increases the complexity by adding additional charge
and thus variation electropherogram. The Figure 3-1 glycans provide 14 standard glycans
all with different glycoform structural types and serve well as inexpensive methods of
structural confirmation. Due to the high separation efficiencies described in Chapter 2,
these glycans can be efficiently separated from each other, and with very small variances
in migration time , making migration-based identification a feasible method.
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Figure 3-1 displays an electropherogram of glycan standards used by the Holland
group. Glycans include those from linear maltooligosaccharides as well as branched
glycans from glycoproteins Rnase B and AGP. This figure was reproduced with
permission from [3]. Copyright 2011 American Chemical Society.

While the use of glycan standards is a frequently used approach for peak
identification, it suffers from two major drawbacks. The first drawback is that, simply, the
Thursday,
September
1, 2011
needed glycan
standard
may not be available to the user through a commercial or

glycoprotein source. The second is due to the increased cost that comes from purchasing,
each particular glycan standard that is of interest. Obtaining and labeling each standard
can be costly and commercial availability of such standards is often a major challenge to
this method of identification. While glycan standards can be obtained from glycoprotein
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sources, the increased time and cost in deglycosylating, labeling, and purifying these
glycans can be prohibitive, and the number of glycoproteins that are well characterized is
few.

3.3.2 Utilization of Lectins and Enzymes for Glycan Characterization
An alternative method of elucidating structure of a glycan of interest is through
the use of highly specific proteins, such as lectins and enzymes. These proteins will
selectively bind or enzymatically cleave only the glycans that have the targeted
characteristic. This method has been frequently used on the bench-top for down-stream
analysis using separations techniques such as HPLC and CE, and mass spectrometry.
However, this method is hindered by the amounts of enzyme or lectin consumed per
analysis, as well as the lengthy incubation times that are a result of free-solution
reactions. Incorporating these proteins within the capillary allows for the reaction volume
to be reduced, and for the incubation times to be reduced by increasing the ratios of
enzyme to glycan per analysis.
In-capillary analyses were performed using a commercially available, automated
capillary electrophoresis system (Beckman P/ACE MDQ). This system is equipped with
temperature-programmable storage for samples and reagents. Although the practical
volume limitations of the Beckman P/ACE MDQ are 20 µL, the actual amount of lectin
injected into the capillary is in the nanoliter range per analysis. A 1.5 psi, 15 sec injection
into a 25 µm inner diameter, 60 cm capillary is only 2 nL. In the 25 µm i.d. capillary this
plug is only ~0.5cm long and is less than 1% of the length of the total capillary. An
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extensive flush in the reverse direction is used prior to each analysis to prevent
contamination from run to run. Additionally, it is common practice to complete a “blank”
reaction in-between lectin or enzyme reactions to ensure this.

3.3.3 In-Capillary Reactions of Glycans to Lectins
The process of in-capillary incorporation and interaction with glycan is depicted
conceptually in Figure 3-2. Prior to analysis the capillary is prepared by briefly coating,
flushing, then filling the the capillary phospholipid at 19℃. At this temperature, the
viscosity of the phospholipid is similar to that of water, and a small plug of lectin may be
hydrodynamically injected into capillary. This lectin plug is bracketed by two small plugs
of separation buffer to prevent the cross-contamination of the lectin with any of the other
vials. The temperature of the capillary is then increased to 25℃, resulting in the
increased viscosity of the phospholipid and the entrapment of the protein lectin within the
capillary. Because the phospholipid material is biocompatible, this entrapment procedure
serves to immobilize the protein without denaturing it. At this increased temperature, the
glycans are injected into the capillary and separated under reversed polarity (usually
400V/cm). The glycans are separated in the absence (top figure) and presence (bottom
figure) of lectin. When lectin is incorporated into the separations capillary, glycans
specific for the lectin are bound, and therefore do not migrate to the detection window.
Thus the incorporation of lectins into the capillary is quick method to discern structural
characteristics and can even be used to simplify complex electropherograms by
selectively removing groups of glycans from analysis.
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pressure inject at low temperature
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inject and separate

lectin plug
Figure 3-2 displays a schematic of how plugs of lectins can be incorporated into a
separations capillary. The top figure shows how glycans (colored bands) would
separate in a capillary with no modifications. The bottom figure shows how glycans
would separate in a capillary with a plug of lectin specific for a single (green)
glycan. As the glycans are separated, and pass through the plug, the species with
the chosen characteristic are bound to the lectin and do not migrate.

enzyme plug

3.3.4 Concanavalin A

pressure
inject atAlow
temperature
Concanavalin
(ConA)
is a lectin derived from Canavalia ensiformis (jack-bean)
raise temperature to gel transition
that is specific for glucose and mannose resides. It has been used in a number of studies
inject,
incubate, and separate
products
for the analysis
of mannose-rich glycans, including methods of capillary affinity
electrophoresis [17] and lectin-arrays [18,19].
A small plug (1psi 7 sec) of 1mg/mL (~9 µM) Concanavalin A in pH 6, 2-(N-

targeted sugar is bound or
4
enzymatically
cleaved
on
protein
mannose glycans from the standard glycans also shown in Figure 3-1. The glycan was

morpholino)ethanesulfonic acid (MES) was used for the in-capillary analysis of high
Thursday, September 1, 2011

separated through the capillary as normal, with no incubation or wait steps. Figure 3-3
shows this electropherogram (top trace), as well as an electropherogram of the same
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glycans through a capillary containing only a buffer blank (pH 6 MES)(bottom trace). No
incubations were necessary for the binding of these glycans to the lectin. Concanavalin A
selects for mannose, and highly-branched mannose, and therefore bound to the highmannose glycans from Rnase B (Man5, Man6, Man7, Man8, and Man9). It is interesting
to note that, despite the relative abundance of these glycans, a high specificity of the
lectin to branch mannose is obtained. This is especially true for the branched mannose
Man5 in comparison to the linear heptamaltose, G7. While the relative concentration of
Man5 is high in comparison to G7, the linear glycan unaffected by the lectin. The
diantennary complex-type glycan AI from α-acid glycoprotein does respond to ConA, but
could be completely removed from the separation with higher concentrations of ConA.
This is because ConA will bind to the Man3 core the glycan. [17].

60

igure X
+ Concanavalin A
G4
0.01 RFU

AII
G5

G6 G7

AI

AIV

AIII

AV

Man5
G4

- Concanavalin A
Man6

AII
G5

12

13

AIV

Man7
G6

14

AI

G7

15

16

Man8

17

18

AIII

19

AV
20

21

22

23

Time (min)
Figure 3-3 displays an electropherogram of glycan standards (high mannose
glycans from RNase B, complex-type glycans from AGP, and linear maltoses)
separated in a capillary containing either a buffer blank, or 1mg/mL Concanavalin
A. Separations were completed in a 60.2 cm, 25 m. i.d. capillary at a field strength
of 400 V/cm. This figure was reproduced with permission from [3]. Copyright 2011
American Chemical Society.
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3.3.5 Use of Enzymes for In-Capillary Analysis
The phospholipid media can be utilized to incorporate proteins into the capillary
without subsequent covalent modification or denaturation. This makes this media
especially useful for the incorporation of bio-active proteins such as exoglycosidase
enzymes. These enzymes exhibit great sensitivity to both residue types (e.g. mannose,
galactose), linkage position (e.g. 1-3, 1-4), and linkage type (e.g. α, β). Exoglycosidases
are well characterized and commercially available through a number of sources. Unlike
the use of lectins in-capillary, the selected glycan is not retained in the protein plug inside
of the capillary. Because the exoglycosidase removes terminal glycan residues, the rest of
the glycan is still fluorescently tagged, but now smaller in size. This results in a change of
electrophoretic mobility, and thus the migration. In this analysis method, the glycans with
the desired characteristics will be identified by a shift in the migration time. This is
demonstrated conceptually in Figure 3-4.
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products
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The process of positioning, incubating, then separating the glycan is part of a
three-step process. The enzyme is introduced into the capillary using the same methods as

pressure targeted
inject at lowsugar
temperature
is bound or
lectin introduction mentioned previously, and immobilized within the capillary at 25℃
raise temperature to gel transition
4
enzymatically cleaved on protein
inject,
incubate,
and separate
by the highly
viscous phospholipids.
The glycan is then injected into the capillary and
Thursday, September 1, 2011
products
moved into the enzyme plug with a brief electrokinetic “push” at low voltage (10kV 30

sec). The glycans are incubated in the enzyme plug for a specified amount of time, and
the reaction products are separated and detected in the capillary. A benefit of using in-

targeted sugar is bound or
enzymatically cleaved on protein

capillary exoglycosidase reactions over bench-top free solution reactions is that
4 the
reaction volume is small (~2 nL). Although commercial exoglycosidase kits require 1

Thursday, September 1, 2011

hour of incubation time, none of the in-capillary incubations presented in these studies
were longer than 20 minutes. Additionally, because the incubation step in the capillary is
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online capillary cleavage:
reduced
enzyme
part
of the program,
a seriesconsumption
of experiments with varying incubation times can be
faster cleavage rates
performed with the same sets of enzyme and glycan. This includes the monitoring of both
reuse of single analyte sample
the disappearance of substrate, the appearance of product, and the appearance of
intermediate products, if possible (Figure 3-5).

0,5,10, or 15 minute incubation in capillary
blank

5 minutes
10 minutes
15 minutes

5

Figure 3-5 displays a schematic of how in-capillary plugs of enzymes can be
utilized
to September
monitor the
of glycan enzymatic products. The top figure shows
Thursday,
1, formation
2011
how glycans (colored bands) would separate in a capillary with no modifications.
The other figures demonstrate the progressive depletion of the original glycan, and
the accumulation of the glycan products.

3.3.6 Mannosidase
High-mannose glycans are of interest in a number of fields of study; for example
high-mannose glycans have been linked as biomarkers for a number of health-related
issues such as breast cancer [20].

To investigate high mannose glycans, the enzyme

α1-2,3 mannosidase was used for in-capillary studies. This enzyme selectively cleaves
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α1-2 and α1-3 mannopyranosyl residues that are commonly found on high-mannose
residues, and would eventually result in a final product consisting of a trimannose core
with a number of α1-6 mannoses residues attached. Because these linkages are specific
for high-mannose and high-mannose hybrid glycans, this enzyme can be used to confirm
structure along with the lectin concanavalin A.
Figure 3-6 demonstrates how this enzyme can be used as a method to distinguish
unresolved glycans. High mannose glycans from Rnase B, as well as linear
maltooligosaccharides were separated in a 40 cm, 50 µm inner diameter capillary coated
and filled with phospholipid. In Figure 3-6-A, the glycan peaks for Man5 and
heptamaltose have overlapped and thus are indistinguishable. By separating these glycans
after increasing incubation times in-capillary, the peak corresponding to mannose 5
decreases in area, revealing the identity of the peak. The linear maltoses are not cleaved
by this enzyme and migrate with the same electrophoretic velocity as those separated in
the capillary in the absence of enzyme. The product peak, which is believed to be from
the cleavage of the α1-3 mannose residue attached directly to the trimannose core, forms
almost completely after 15 minutes, rather than the 1 hour required for the protocols
provided by the manufacturer. The 20 µL samples of both glycan and enzyme may be
used for multiple reactions, and under different incubation conditions.

65

en con A is
separation in
g ConA. The
captured the
on conditions
of pressure to
tive to that in

ain a malto-

Figure 6. Integration of an enzyme (R1-2,3 mannosidase) in the

Figure 3-6 demonstrates how the enzyme α1-2,3 mannosidase can be used for inseparation
to probe
structural
of glycans.
The separation
in
capillary
analysis
of glycan
samples. Afeatures
sample containing
high-mannose
sugars
traceRnase
A was
subject
to 15 min
with no
mannosidase.
from
B and
linear maltoses
wasincubation
separated following
various
incubation The
times
in
a
plug
of
α1-2,3
mannosidase,
resulting
in
the
progressive
cleavage
of the
lower electropherograms are obtained following an incubation
time
Mannose 5 glycan, and the formation of its reaction product, which overlaps with
of 5
(C),
andwas
15reproduced
min (D) with
with
the enzyme.
separation
the
G6(B),
peak.8This
figure
permission
from [2].The
Copyright
2010
American
Chemical
Society.
conditions are identical to that obtained in Figure 2, trace B.

which it can incorporate carbohydrate-binding lectin as well as
enzymes specific to cleave mannose residues to assist in the
structural elucidation of unknown glycans. The elimination of covalent 66
surface modification and the ease with which the preparation is

3.3. 7 Galactosidase
Galactose is one of the most common glycan residues in complex-type
glycosylation, making it an important feature analyze. In addition to a number of general
β-galactosidase enzymes, positionally specific galactosidase enzymes are readily
available including those that target β1-3, β1-4, β1-3,4,6, and β1-3,6 linkages. β1-4
Linked galactose, a common terminal residue found in complex-type glycans, was the
target of an on-line reaction using the enzyme β1-4 galactosidases. This enzyme was used
to probe a solution of complex-type glycans from asialofetuin, a desialated version of
bovine fetuin (Figure 3-7). Asialofetuin has three glycan structures, diantennary and
triantennary structures that are identical to that as glycan from AGP (AI and AII), as well
as a isoform of AII known as FII. FII has an identical structure to that of AII, with the
exception that one of the glactose residues is attached with a β1-3 rather than β1-4
linkage. This small change in overall glycan structures makes the resolution of these two
isoforms difficult for most separations methods and speaks to the ability of phospholipid
additives for high resolution and efficiency separations. Figure 3-7 also demonstrates
how, with different incubation times, the progressive disappearance of the substrate and
appearance of product peaks can be monitored using the same initial samples of enzyme
and glycan.
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3.3.8 Neuraminidase
The existence of sialic acid can greatly complicate the separation and
identification of glycans for a number of analytical methods including liquid
chromatography and mass spectrometry. Sialic acid residues provide additional negative
charge to the glycan. Sialic acids are also thermally labile and can detach following
application of heat and acid. Often, the sialic acid content may analysis to analysis. Mass
spectrometric methods of analysis often require methylation and derivatization of sialic
acids to prevent their detachment prior to analysis. The affect of sialic acids are
demonstrated in Figure 3-10-A, where glycans from α acid glycoprotein (AGP) are
separated without prior removal of the sialic acid. Although there are only 5 major forms
from AGP, the number of variable forms from sialic acid results in the number of peaks in
the electropherogram. Therefore, it is common practice to remove sialic acids from
glycans prior to analysis, by incubating the glycan solution with the enzyme
neuraminidase. By incorporating this enzyme in-capillary, a simpler electropherogram
can be obtained without extended incubation times.
Neuraminidase cleaves terminal sialic residues rapidly. On-line incubation times
of 5 minutes or less are sufficient to remove all sialic acid. The desialylation of AGP
shown in Figure 3-10-B was completed after a 5 minute incubation. Neuraminidase can
also be incorporated with other enzymes as a discrete plug, or as part of an “enzyme
cocktail” plug, where the enzyme is mixed with another prior to injection.
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3.3.9 Multiple enzyme Methods
Exoglycosidase enzymes selectively target the terminal residues of a glycan.
Therefore multiple enzymes can be used in combination to systematically determine the
full structure of the glycan. In a bench-top analysis, this is accomplished by sequentially
treating the glycan with multiple enzymes, sequentially. The first enzyme is added,
reacted, and the products are analyzed, then the sample is interacted with the second
enzyme and so on. By scaling this model to the microscale, numerous experiments may
be conducted using a single glycan samples and pristine solutions of enzymes, with the
enzymatic reaction being completed within the capillary.

3.3.10 Off-line sequencing model: AGP
Enzymes can be utilized in combination to progressively clip away layers of
residues, revealing the overall structure of the total glycan. This process is demonstrated
for a single glycan (AV) in Figure 3-8. To discern the structure of this glycan,
exoglycosidases are systematically applied to the glycan to remove each outer layer of
residues with analysis in between each step. If CE is utilized for these analysis steps, the
cleaved glycan will respond to by a different migration time, as the electrophoretic
mobility has changed in response to the truncated glycan. With the exception of
desialation, which removes additional negative charge in addition to the residue, all of
these cleavage steps result in an increased electrophoretic mobility and thus a shorter
migration time. A greater migration shift can reveal the number of residues that have been
removed during each step.
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B. α-fucosidase
C. β1-4 galactosidase
D. β-N-acetylglucosaminidase

Figure 3-8 demonstrates how multiple enzymes can be used in conjunction to
determine the sequence of a complex glycan. The complex-type glycan shown (AV
from AGP) has sialic acid, galactose, acetylglucosamine, and fucose glycan
residues all attached to it’s mannose core. By using a number of enzymes in
conjunction with each other the structure of the original glycoform can be deduced.
13
Thursday, September 8, 2011

To demonstrate how these enzymes can used to sequence glycans derived from a
glycoprotein, a multi-step enzymatic reaction on the bench-top was conducted using the
carbohydrates derived from α acid glycoprotein (AGP). The original, sialylated glycans
are shown in Figure 3-9-A. When this glycan sample is modified with the enzyme
neuraminidase the negatively charged sialic acid residues are removed, resulting in a
reduced charge to size ratio and a longer migration time. Because this source of variable
charge is removed, the five major glycoforms of AGP are shown in the resulting
electropherogram, Figure 3-9-B. This glycan solution is then reacted with α fucosidase,
with the resulting electropherogram shown in Figure 3-9-C. This affects the two glycans
containing fucose (AIII and AV) and the reaction products collapses into the AII and AIV
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glycans. The sample is then reacted with β1-4 galactosidase with the results shown in
Figure 3-9-D. All of the galactose in AGP are removed, resulting in dramatic migration
shifts in the three remaining peaks.

The resulting solution is then reacted with β-N-

acetylglucosaminidase with the results shown in Figure 3-9-E. This reaction results in a
single product, as all glycans have been cleaved down to the common, N-glycan
trimannose core. The peak labeled with an asterisk (*) is a byproduct of the APTS
labeling reaction and was used in this experiment as a migration time standard.
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Figure 3-9 demonstrates how multiple enzymes can be used in conjunction to 16
determine the sequence of a complex glycan. Glycans derived from AGP were
progressively treated with the exoglycosidases neuraminidase, α fucosidase, β1-4
Wednesday, October 5, 2011
galactosidase, and β-N-acetylglucosaminidase. These reactions progressively clip
away successive layers of glycans until that all that remains is the trimannose core
(shown in Figure 9-E)

73

3.3.11 In-Capillary Sequential Enzymatic Reactions:
The use of multiple enzymes that target only the terminal glycan residues can be
used to glean structural information. However, this approach requires significant amounts
of enzyme and sample The increased time to perform all of these bench-top enzymatic
reactions is also a disadvantage. By incorporating these enzymes into the capillary, these
sequential analyses can be completed without utilizing the entire glycan sample or
consuming significant volumes of enzyme. A glycan sample can be used for numerous
analysis without affecting the original sample. Because the interaction with protein
occurs in the separation capillary, no sample cleanup following the enzymatic reaction is
necessary.
To demonstrate how multiple-enzyme plugs inside of the capillary can be utilized
to discern structure, the two enzymes neuraminidase and β1-4 galactosidase were use
separately and together to probe solutions of glycans from AGP. Prior to injection of the
glycan into the capillary two discrete plugs are pressure injected into the capillary,
separated by a small plug of of buffer. The glycan is injected into the capillary then
electrokinetically moved onto the first plug of enzyme and incubated. The glycan is then
electrokinetically moved onto the second plug, incubated, then separated through the
capillary.

The resulting electropherograms are shown in Figure 3-10. The first trace

shows a separation of glycans from AGP through a capillary that contains no enzyme
only blanks consisting of pH 6 citrate buffer. The many sialyated glycans can be seen by
this electropherogram. These sugars were incubated for 5 minutes in a small plug of the
enzyme Neuraminidase prior to the separation step. The five major desialylated.
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glycoforms as seen in Figure 3-10-B. To determine the galactose content of these five
glycoforms, the final trace demonstrates the use of two enzymes. In this
electropherogram, glycans are injected and moved onto a plug of neuraminidsae,
incubated for 5 minutes, then moved onto a plug of β1-4 galactosidase, incubated for 10
minutes, then separated through the rest of the capillary. As can be seen in figure 3-10-C,
all of the glycans have been shown to be affected by the enzyme, by both the reduction in
peak area, as well as by the formation of product peaks.
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Figure 3-10 demonstrates how multiple enzymes with a separation capillary to14
sequentially remove terminal glycan residues, determining the overall structure of
the glycan.
Wednesday,
OctoberFigure
5, 201110-A demonstrates an electrophoretic separation of glycans from
AGP, that are sialyated. These highly complex glycans are greatly simplified when
they are enzymatically treated with the enzyme Neuraminidase in-capillary for 5
minutes. (Figure 10-B). When the glycans are are injected then injected for 5, then
10 minutes in Neuraminidase and β1-4 galactosidase respectively, it can be noted
that all major isoform glycans react. This indicates that all major isoforms of AGP
contain sialic acid and β1-4 galactose
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3.4 Conclusions
The incorporation of glycan-specific proteins such as lectins and enzymes is a
useful approach to elucidate glycan structure and composition. Phospholipid additives
support the incorporation of protein-based selection agents without the need for covalent
modification. This method has been shown to be effective in a variety of capillary inner
diameters. Utilization of an in-capillary approach to lectin capture and enzymatic
cleavage has a number of advantages of bench-top analyses including reduced reaction
times, reduced consumption of reagents, and the utilization of a single sample of glycans
for a multitude of analyses. The lectin concanavalin A, as well as the enzymes α1-2,3
mannosidase, neuraminidase, and β1-4 galactosidase were all used to demonstrate how
in-capillary interactions can be used to probe solutions of glycans.
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Chapter 4
Applications of Method to Biological Samples: MCF7
and Trastuzumab
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4.1 Introduction:
Glycosylation exists as one of the primary post-translational modifications of
proteins, and has extensive biological implications. Glycosylation also plays a vital role
in the functionality of these proteins, as changes in the glycan structure can result in
altered protein structure and changes in cellular signaling. This is especially important in
the search for biomarkers of disease and the development of biological therapeutics such
as IgG antibodies. This chapter covers how phospholipid-assisted capillary
electrophoresis can be utilized to efficiency separate and analyze glycans, as well as to
characterize these two samples by incorporating lectins and exoglycosidase enzymes into
the capillary. Cancerous tissues have been known to display abherrent glycosylation [1].
Therefore the method was used to analyze the total glycan content from immortalized
breast cancer cell line MCF7. This data has been published in reference [2]. This method
was also applied to analysis of glycans from the therapeutic antibody Trastuzumab
(Herceptin®), a monoclonal antibody whose glycosylation has been well characterized
[3]. This data has been published in reference [4].

4.1.1 Glycomics and Clinical Biomarker Research
The total glycan content of a cellular sample can host a diverse variety of
oligosaccharides. Glycoproteins in eurkaryotic systems occur in all cellular compartments
where they are attached to linked to peptides through serine or threonine (O-linked), or
asparagine (N-linked) residues [5]. Glycans can also be attached to lipids, such as the
glycosphingosine, ceramide [6].

Unlike other protein modifications such as
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phosphorylation, acetylation, or methylation, glycosylation poses a challenge to analysis
due to extensive variation in glycan monomer composition, linkage between monomers,
and overall placement. Further adding to the difficulty in studying glycan structure and
function it should be noted that, unlike nucleic acids and proteins, glycans are not linked
back to the genome, but result from the numerous and coordinated actions of highly
specific glycosyltransferases that can change based on numerous localized conditions
[7]. These events result in highly variable solutions of glycoforms, made of very slight
alterations in the actual glycan structure.

4.1.2 MCF-7
Protein glycosylation is one of the primary post-translational modifications, and
results in extensive biological implications. Changes in the glycosylation of proteins has
been shown to change as a result of malignant transformation, making glycosylation
alteration a common feature of disease such as cancer [8]. MCF-7, which stands for
Michigan Cancer Foundation Line 7, was established in Detroit in 1973, and is the most
commonly used breast cancer cell line in the world [9]. As of 2003, this line has been
cited in literature more than 5 700 times [10]. As this line is well-documented, it is
frequently used as a model line to characterize advances in instrumentation in
methodology in proteomic studies. Because glycosylation has such a profound effect on
cellular biology, monitoring of cellular glycosylation is vital in in-vitro cellular studies.
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4.1.3 Therapeutical Biologics and Antibodies
Total revenues of antibody-based therapeutics generated about 20 billion USD in
2007 [11]. Sale growth forecasts for antibody therapeutics are 14% (vs 0.6% for small
molecule- based therapeutics). Antibody-based therapeutics have a relatively high success
rate from clinical to the licensure (25-29% for antibodies vs only 11% for small-molecule
drugs) [12] It was reported by Reichert in 2008 that a total of 205 mAbs were in clinical
trials. It was also estimated that from 1988 to 2006, 17% of all humanized mAb
candidates that reached clinical trials were eventually approved by the FDA (as opposed
to only 11% of small molecule drugs) [13].
Biosimilar antibodies are “generic” (it is important to use the term “generic”
cautiously because generic versions of off-patent small-molecule drugs are exact copies
of the original drugs) versions of an original drug, that contain the same amino acid
sequence but are produced from different clones and manufacturing processes. These
molecules may have different glycosylation patterns as well as other micro-variants that
may affect quality, safety, and potency. Bio-better antibodies target the same validated
epitope but have been engineered to have improved properties. One of the most popular
methods to do this is through changes in the glycosylation. [12]

4.1.4 Antibody Structure and the Effects of glycosylation
IgG antibodies are comprised of two heavy and two light chains held together by
covalent and non-covalent bonds to form three independent protein moieties connected at
a flexible linker known as the hinge region (Figure 4-1). The two Fab fragments serve as
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the antigen-binding regions of the antibody, while the third Fc fragment, along with the
site of glycosylation, at asparagine at position 297, plays a major role in the
communication and interaction with the immune system and cell surfaces [14]. The
glycan is attached to the amino acid prior to the secondary, tertiary, and quaternary
structure is formed, and is a major factor in the overall structure of the protein. Following
the folding steps of the antibody, the glycan undergoes a number of glycan trimming and
addition steps[15] . The basic structure of this N-linked glycan is that of a core structure
comprising N-acetylglucosamine and mannose, with a variable region at the ends [16].
The type of glycosylation from IgG antibodies can vary widely; although there is very
little sialyation (<10%), antibody heterogeneity can result in a potential of up to 128
different glycoforms [17]. Utility of the the antibody as a therapeutic is through several
possible functions. The primary function is the use of the antigen binding regions to bind
a specific target, halting the pathway that it would be involved with. However, a number
of other effects of antibodies are being engineered, including extensions of biological
half-life and effector functions, such as antibody-dependent cell-mediated cytotoxicity
(ADCC). Extending an antibody’s half-life provides a number of benefits, including an
improved bioavailability and reduced amount or frequency of dosing [14]. These methods
may be used to improve the efficacy of the drug or decrease the cost of treatment to the
patient. Many biotherapeutics utilize effector functions such as antibody dependent cellmediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) as a major
part of the drugs mechanism in the body. These modes of targeting cells for active lysing
by the immune system is a potent method therapy for a number of diseases. When this
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method of alteration is considered; however, the antibody is often engineered to shorten
the biological half-life, so that patient does not suffer from undue toxicity [14]. Current
efforts are underway to enhance these effects by engineering the glycan structure.
Methods to alter antibody glycosylation include changes in the cell culture production
such as the choice of cell line, nutrient availability, amount of dissolved oxygen or
ammonia, pH, culture viability, growth phase, and temperature [15]. Host cell lines, such
as Chinese hamster ovary (CHO) have been selected to express antibodies with altered
glycosylation such as increased amounts of bisecting N-acetylglucosamine or reduced
amounts of fucose which serves to increase ADCC activity [18]. It is therefore necessary
for both the manufacturer, as well as regulatory agencies, to profile and monitor the
structural characteristics of these glycans.
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Figure 4-1 Figure 4-1 shows a general depiction of a whole IgG antibody and a general
depiction of the glycosylation found N-linked to asparagine at position 297.

4.1.5 Trastuzumab (Herceptin)

The human epidermal growth factor receptor family of of four receptors (HER1,
HER2, HER3, and HER4, also known as ErbB) are tyrosine kinase receptors that
normally regulate cell growth and survival. These receptors have an extracellular domain
for ligand binding, a transmembrane segment, and with the exception of HER3, an
intracellular tyrosine kinase domain [19]. The extracellular domain of HER2 is unique in
this family because unlike the other three HER receptors, HER2 can adopt a
conformation that permits dimerization when there is a lack of ligand [20]. This binding
activates signal-transduction cascades of these receptors that promote cellular
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proliferation, survival, as well as mobility and invasiveness [21]. The over expression of
HER2 has been observed in the 20 to 30 % of breast cancer that has been classified as the
most aggressive and with the worst prognosis. [22,23].
Trastuzumab (Herceptin ®) is a recombinant monoclonal humanized IgG
antibody that contains two antigen-binding sites specific to the extracellular domain of
the HER2 receptor, effectively blocking the receptor for ligand binding or dimerization.
This prevents activation of the intracellular tyrosine kinase, and the cascade of events
resulting in unchecked cellular growth [24]. Trastuzumab was produced by Genentech
and was approved for the treatment of patients with HER2 over expressed metastatic
breast cancer by the Food and Drug Administration (FDA) in 1998. Trastuzumab has
been shown effective when used in conjunction with standard chemotherapy, and has
been shown to extend the time to disease’s progression, increase response rates, and
result in a longer median survival rate [25]. Trastuzumab is rarely prescribed as a standalone treatment, and is beneficial for

only a small percentage of patients (only

approximately 20%) when it is not combined with a secondary treatment such as cisplatin chemotherapy [26]. As possible mechanisms of resistance are being investigated
[27] a number of alternative therapeutics focusing on the same targets have been
developed. Trastuzumab’s effectiveness has been shown to improve with the removal of
fucose from the existing glycan structure. Removal of fucose has been shown to greatly
enhance ADCC, and thus the effectiveness of the drug to target cancerous cells. A
recently study showed that defucosylated trastuzumab doubled the survival time in
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comparison to fucosylated trastuzumab in preclinical models of HER2 overexpressed
breast cancer [28].

4.1.6 Quality by Testing vs Quality by Design
The historical approach toward the approval of pharmaceutical products involved
the identification of the process parameters

at each stage of development that have

critical influence on product quality, then testing the end product to validate the process.
This process, known as Quality by Testing has a number of important disadvantages,
including the fact that any change in the manufacturing process requires validation,
discouraging companies from changes, improvements, or optimization of the
manufacturing process. The major regulation bodies in the United States and Europe
(USFDA and EMEA) now encourage the incorporation of Quality by Design into the
production pipeline. Quality by Design involves the understanding and utilization of indepth knowledge of the product and mechanisms at every of production. Quality by
Design concepts include a definition of the desired performances (clinical or in vivo),
identification of critical quality attributes and the process parameters that affect these
attributes, and sets of analyses during processing for the dynamic control of
manufacturing to ensure that the defined product performances are achieved [29].
Because glycosylation is responsible for the considerable variability of mAb products,
rapid, efficient analyses of glycosylation is vital to this industry.
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4.2 Experimental
4.2.1 Chemicals and Materials:
Reagents were obtained from a variety of manufacturers. Sigma Aldrich (St.
Louis, MO, USA) was the source for asialofetuin from fetal calf serum, 3-(Nmorpholino)-propanesulfonic acid (MOPS), calcium chloride dihydrate, sodium chloride,
maltooligosaccharide standards and sodium hydroxide. Methanol and α1-acid
glycoprotein (AGP) were purchased from EMD Biosciences (La Jolla, CA). Ethanol was
obtained from AAPER Alcohol (Shelbyville, KY). 1,2-dimyristoyl-sn-glycero-3phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) were
obtained from Avanti Polar Lipids (Alabaster, AL). 1-aminopyrene-3,6,8-trisulfonic acid
(APTS) was purchased from Biotium (Hayward, CA). Sodium cyanoborohydride
(NaCNBH3) was acquired from Strem Chemicals (Newburyport, MA). Triethylamine,
acetonitrile, and citric acid were acquired from Fisher Scientific (Pittsburgh, PA). Fetal
bovine serum was obtained from Thermo Scientific (Rockford, IL). Trastuzumab was
obtained from Genentech (San Francisco, CA, USA). Ribonuclease B (Rnase B), α1-2,3
mannosidase, β1-4 galactosidase, neuraminiase, β-N-Acetylglucosaminidase, and a
peptide N-glycosidase (PNGase F) kit, were obtained from New England Biolabs
(Ipswich, MA). A G7 10X reaction solution composed of 0.5M sodium phosphate
buffered at pH 7.5, a glycoprotein denaturing solution containing 5% sodium dodecyl
sulfate (SDS), and 0.4 dithriothreitol (DTT), and 10% solution of nonionic surfactant
NP-40 were included in the PNGase F kit. A G1 10X reaction solution composed of 0.5M
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sodium citrate buffered at pH 6 was provided in the neuraminidase kit. An Elga Purelab
ultra water system (Lowell, MA) was used to provide deionized water.

4.2.2 Culture of MCF7 Cells and Protein Isolations
MCF7 cells (ATCC, Manassas, VA) were cultured by David Lowrey and Linda
Sargent at the National Institute for Occupational Safety and Health (Morgantown, WV).
Cells were cultured with Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum. The total protein was isolated from
approximately 10 x 106 MCF7 cells in a T75 flask. Two mg/mL of total protein was
isolated when the cells were approximately 70% confluent. The protein was extracted in
50mM Tris-HCl, 1% Triton, 1.5 mM MgCl2, 150 mM NaCl, and protease inhibitors. An
83µg sample of the isolated protein fraction taken from the MCF7 cells was labeled with
APTS as described.

4.2.3 Preparation and Derivatization of Glycans from MCF7 and Trastazumab
Glycans derived from glycoproteins (Branched glycan standards, glycans from
MCF7, and glycans from Trastuzumab) were prepared as follows. Glycans were removed
from protein sources using a PNGase F kit using a protocol based on the kit from the
manufacturer. Briefly the protein is denatured using a solution containing SDS and DTT
and heating at 95℃ for 10 minutes. The nonionic surfactant NP-40 is then added to the
solution to prevent the DTT from denaturing the enzyme PNGase F, which immediately
added afterward. This reaction was incubated at 37 ℃ overnight, rather than the 2 hours
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suggested by the protocol. The next day, a 3X volume of ice-cold ethanol was added to
precipitate the protein. The solution was centrifuged at 4℃ at 10 000 rpm for 10 minutes.
The liquid fraction containing cleaved glycans was dried using a Savant SpeedVac
concentrator (ThermoScientific, Waltham, MA). The dried glycans were reconstituted in
1 µL of a 0.2 M solution of APTS dissolved in 1.2 M citric acid, along with 1 µL of 1 M
NaCNBH3 in deionized water. The solution was thoroughly mixed before being incubated
overnight at 37 ℃. 100 µL of deionized water was used to stop the reaction. If needed,
the sialic acid was removed by adjusting the pH of the glycan solution to 6 with sodium
hydroxide then incubating it overnight with neuraminidase. If necessary, a 10 kDa
molecular weight cut off filter (Sartiorius, Stonehouse, UK) was used to remove the
neuraminidase followed by removal of excess APTS by a Discovery DPA-6S solid phase
extraction cartridge (50 mg packing, Supelco, Bellefonte, PA). A flush of 95:5 (v/v)
acetonitrile:water was used to prepare the cartridge prior to use. APTS was eluted from
the extraction cartridge with a solution containing 95:5 (v/v) acetonitrile:water containing
50 mM trimethylamine. An aqueous solution of 50 mM triethylamine was used to elute
the retained glycans from the cartridge. The glycan solution was evaporated to dryness
and the reconstituted in 100 µL deionized water and stored at -20 ℃. Following labeling
of the MCF7 glycans with APTS, a 1kDa molecular weight cutoff filter (MWCO) was
used to remove APTS labeled- small molecules, such as monosaccharides. Prior to
deglycoyslation and labeling of Trastuzumab, a 10 kDa MWCO filter was used to remove
trehalose and other stabilizes from the protein antibody.
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4.2.4 Preparation of Phospholipid Additive
Preparations of phospholipids were comprised of 5 %, [DMPC]/[DHPC] (q value)
= 0.5 were used for coating of the capillary, which serves to suppress the electroosmotic
flow, and to passivate the surface from nonspecific interactions. Another phospholipid
preparation of a 10 %, q = 2.5, phospholipid solution was used for the separation media,
due to it’s thermally-switchable gel-like viscosity. These phospholipids were prepared by
weighing out the appropriate masses of dry DMPC and DHPC, then adding 100 mM
aqueous MOPS buffered to pH 7. After the solution was thoroughly mixed, the
preparation was subjected to a minimum of three freeze-thaw cycles and centrifuged for
10,000 rpm for ten minutes. The phospholipid preparation was stored at -20 ℃, and was
thawed and vacuum degassed prior to use.

4.2.5 Capillary Electrophoresis
Separations were performed using a P/ACE MDQ Capillary electrophoresis
system (Beckman Coulter, Fullerton, CA, USA) equipped with laser induced
fluorescence detection (air cooled argon ion laser, λex = 488 nm, λem = 520 nm). The
fused silica separation capillary had a 25 µm internal diameter and a 360 µm outer
diameter (Polymicro Technologies, Phoenix, AZ, USA) with an effective length of 50.0
cm and a total length of 60.2 cm. Capillaries were subject to the following flushing
sequence daily: 1 M NaOH for 30 minutes at 170 kPa (25 psi), deionized water for 15
minutes at 170 kPa (25 psi), methanol for 15 minutes at 170 kPa (25 psi), and 15 minutes
of water at 170 kPa (25 psi). Following this flushing sequence, the capillary was
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passivated with a phospholipid coating with a 5 %, q = 0.5 phospholipid preparation
containing 1.25mM calcium. This semi-permanent coating was applied for 20 minutes at
170 kPa (25 psi) followed by a 2 minute MOPS flush at 170 kPa (25 psi) to remove
excess phospholipid and from the capillary. A brief pre-coat was applied prior to each
run using the following protocol at 170 kPa (25 psi) with the capillary held at 19℃: q =
0.5, 5% phospholipids for 3 minutes, MOPS for 2 minutes, and q = 2.5, 10%
phospholipids for 3 minutes. If enzyme was being used in-capillary, an additional 3
minute 170 kPa (25 psi) MOPS flush was performed in the reverse direction before this
sequence, to expel any enzymes from the capillary, and to prevent fouling of the capillary.
When the room temperature was higher than 22 ℃, a portable air conditioner was used to
provide ambient thermal control. Injections into the capillary were carried out in three
steps. First, a plug a MOPS was injected into the phospholipid filled capillary (7 sec, at
6.9 kPa) at 19 ℃. The capillary temperature was then heated to 25 ℃, resulting in the
viscosity of the q = 2.5 10 % phospholipid filling to increase to a gel-like consistency.
The glycan is then electrokinetically injected into the capillary. Finally a post-plug of
MOPS was pressure injected (5 sec, 3 kPa). Separations were carried out at 400 V/cm
under reversed polarity. Data collection and analysis were performed using 32 Karat
Software version 5.0 (Beckman Coulter).

4.3 Results and Discussion
Chapter 3 discussed how glycan-specific lectins and enzymes may be used to
analyze solutions of glycans for structural characterization. In this chapter, these methods
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of analysis are used on two different biological samples, demonstrating two different
types of analyses.
In-capillary interactions may be used to probe and simplify highly complex
samples of unknown glycans, such as those taken from the protein fraction of cellular
samples. N-linked glycans from the immortalized human breast carcinoma cell line
MCF7 were analyzed with capillary electrophoresis. This highly complex sample was
probed with lectins and enzymes to discern the overall characteristics, providing an
analysis method that can be used monitor changes in the overall glycan composition.
These changes may act as biological “clues” to reveal changes that are relevant to cancer.
This method was also used on glycans with the uncharacterized low abundance glycans
from the therapeutic antibody Trastuzumab, to discern the amount of glycans containing
sialic acid.
The incorporation of enzymes into capillary may also be used to target and
determine the sequence of specific glycans. Various exoglycosidase enzymes are used in
combination to systematically cleave terminal residues, revealing the sequence of the
overall glycan structure. This method provides a rapid, low-tech method of determining
sequence without the use of sophisticated instrumentation, such as mass spectrometry.
This method is used to sequence the major isoform glycans taken from the therapeutic
antibody Trastuzumab.
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4.3.1 Separation of Glycans from MCF7 Cells and Identification with Glycan
Standards
Glycans from the immortalized breast cancer cell line, MCF7, were labeled with
APTS and separated using phospholipid-assisted capillary electrophoresis. The use of
phospholipid additives as an easily incorporated, gel-like separations media provides
superior separations efficiencies. These glycans were separated with efficiencies as high
as 640 000 theoretical plates. The excellent separations efficiencies as a result of the
phospholipid materials allow for superior resolutions of high abundance glycans, as well
as the detection and separations of low abundance glycans, as seen in Figures 2 and 3.
Two of the low abundance peaks (as seen in Figure 3) were identified with the glycan
standards mannose 5 and mannose 6.

4.3.2 Analysis of MCF7 with Concanavalin A
Phospholipids provide excellent media for the incorporation of proteins such as
lectins and enzymes. Because phospholipids are naturally the components of cellular
membranes, phospholipids are inherently biocompatable and do not result in
denaturation. Alternative methods of protein incorporation for analysis usually involve a
method of conjugation such as biotin-streptavidin or covalent modification of the protein,
which can result in denaturation of the protein and/or modification of the binding or
reaction pockets of the protein. These may reduce subsequent protein binding or
enzymatic activity. The methods of conjugation often utilize buffers, ionic strengths, and
pHs that can further damage the enzyme, and require lengthy cleanup steps prior to

96

utilization. In contrast, using the temperature-dependent viscosity of the phospholipid to
immobilize the enzyme within the capillary is achieved without modifications to the
protein or phospholipid.
The lectin concanavalin A was used to reduce the complexity of the
electropherogram of glycans taken from MCF7 cells. Analyses with off- or on-line of
incubations of concanavalin A select for mannose-rich glycans that bind with high
specificity, especially to glycans such as mannose 5 and mannose 6. The
electropherogram shown below displays the major and minor glycans from MCF7.
Glycans that responded to concanavalin A and thus had these structural characteristics are
shown. The coefficient of variation of peak area was less than 10 %. Therefore the
criterion for peaks that responded to enzyme or lectin was chosen to be 15 %. Any peak
that responded by more than 15% was denoted in Figures 4-2 and 4-3. Mannose
composition of the MCF7 glycans were primarily identified from using an off-line
incubation with concanavalin A. These experiments showed that the majority of glycans
taken from the MCF7 cell line are structurally high in mannose, a characteristic that is
supported in other literature sources [29]. The analyte peak identified as mannose 5 by
glycan standards did not respond to concanavalin A. This may be because of the low
abundance of this peak and competing higher affinity of other mannose-rich species.
Additionally others have reported that lectins may display unusual interactions that do not
obey predicted epitope binding [30].
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Figure X is the electropherogram of the labeled glycan fraction derived from MCF7 cells.
Glycan composition is interrogated using the enzymes !1-4 galactosidase, "1-2,3
mannosidase, or the lectin concanavalin A.
Figure 4-2 is the electropherogram of the labeled glycan fraction derived from MCF7
cells. Glycan composition is interrogated using the enzymes β1-4 galactosidase, α1-2,3
mannosidase, or the lectin concanavalin A.This figure was reproduced with permission
from [2]. Copyright 2011 American Chemical Society.

4.3.3 Analysis of MCF7 with galactosidase, mannosidase
Friday, August 5,The
2011
enzymes α1-2,3 mannosidase and β1-4 galactosidase were used for in-

capillary interactions with the MCF7 glycans. The enzyme α1-2,3 mannosidase cleaves
terminal α1-2 or α1-3 mannose residues and can be used along with the lectin
concanavalin A to confirm the characteristics of a high-mannose glycan. The enzyme

98

Figure X
β1-4 galactosidase selectively cleaves terminal β1-4 galactose residues and is an indicator
of branched glycan species.
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Figure X is the electropherogram of the labeled glycan fraction derived from MCF7 cells
with the figure size blown up to show the low abundance peaks. Glycan composition is
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Glycan
concanavalin A.
composition is probed with the enzymes β1-4 galactosidase, α1-2,3 mannosidase, or
the lectin concanavalin A. This figure was reproduced with permission from [2].
Copyright 2011 American Chemical Society.
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4.3.4 Identification of the major glycans from Trastuzumab
Glycosylation of the humanized immunoglobulin IgG1, Trastuzumab is primarily
fucosylated N-linked biantennary complex glycans [17,31]. The major glycans from
Trastuzumab are shown in Figure 4-4. These glycans have been confirmed through a
number of literature sources and comprise 99% of the major glycans from the antibody.

G0

G0F

Fuc

G1F G1F’ G2F

GlcNAc

Gal

Man

Figure 4-4 displays the highest abundance structures characterized for Trastuzumab
(Herceptin ®), as well as the naming used for this study.

4.3.5 Separations of glycans from Trastuzumab
Glycans from Trastuzumab were labeled with APTS and separated using
conditions previously reported. The results are shown in Figure 4-5. A 60.2 cm, 25 µm
inner diameter capillary was coated with Q 0.5 5 % phospholipid, rinsed with MOPS,
then filled with Q2.5 10 % phospholipid. Glycans were injected, then separated using a
field strength of 400 V/cm. The major abundance glycans from Trastuzumab had

4
separation efficiencies ranging from 410,000 plates (G0F) to 510, 000 plates (G2F). The

Wednesday, October 12, 2011
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identities of these glycans were determined based on migration order and abundance
based on characterization by CE and other methods in the literature. Other reported
methods utilizing capillary electrophoresis utilize linear polyacrylamide gel separation
media [31] and the same APTS tagging methods used in this study. However the
efficiencies of separation were only an estimated 65,000 (value based on hand
calculations from figures) compared to our 510,000. An additional benefit of the
phospholipid separations media is that the low abundance glycans, which make up ~1 %
of the total glycan can be efficiently resolved and detected. These glycans, which are not
well-characterized in literature, are shown in Figure 4-5-B.

Three of these low-

abundance glycans were identified as high mannose structures (mannose 5 and mannose
6) as well a a branched dianntennary structure (AI). Although the use of glycan standards
can be utilized to confirm structural identity of glycans from a sample, the high cost and
limited commercial availability prevent this method from being truly viable, especially
for users with limited resources.
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Figure X is the electropherogram of the labeled glycan fraction derived from Trastuzumab.
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4.3.6 Characterization of sialyated glycans from Trastuzumab
The determination of the amounts of sialic acid (N-Acetylneuraminic acid) is
beneficial to biotherapuetic monitoring and production. Although sialic acids constitute
<10% of glycans derived from IgG antibody, they are nonetheless a valuable constituent.
Terminal sialic acid has been found to increase the circulating half-life of a biotherapeutic
drug, and thus its efficacy [30]. Sialic acids pose difficulty for analysis because, unlike
other glycan residues, they

each provide a minus one charge, altering the expected

migration time. They are also thermally labile and hydrolyze at low pH, which poses a
challenge to analysis with mass spectrometry. Sialic acids are commonly removed from
glycans prior to analysis with the enzyme neuraminidase, which is fast-acting and
commercially available through a number of sources. To probe the solution of glycans
taken from Trastuzumab, a small plug of neuraminidase in pH 5.0 citrate buffer was
injected into the capillary (1.5psi 15 sec). The glycan was injected into the capillary,
electrokinetically moved onto the enzyme plug and was subjected to a 5 minute
incubation time, then separation through the capillary. The resulting electropherograms
are shown in Figure 4-6-B, which is an expanded view of the low abundance glycans.
The solid trace is of a separation following incubation for 5 minutes in a blank containing
only pH 5 citrate buffer. The dashed trace is following incubation for 5 minutes in a plug
containing the Neuraminidase enzyme. The four low-abundance glycans from
Trastuzumab that are denoted in Figure 6 responded to the enzyme. As can be seen in
Figure 4-6-B, which is a full-scale view of the same electropherograms, these glycans
constitute only a minor portion of the total glycan composition. Based on this study and
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following comparison of the glycan areas, only ~1% of the total glycan content of
Trastuzumab is sialyated.
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Figure X is the electropherogram demonstrates the use of the enzyme Neuraminidase for
probing low abundance sialated glycans from Trastuzumab. The low abundance glycans
that responded to Neuraminidase are denoted in Figure X-A and shown in Figure X-B.
Glycans were incubated with an in-capillary plug of Neuraminidase for 5 minutes prior to
separation and analysis with CE-LIF.

Friday, August 5, 2011

104

Figure 4-6 is the electropherogram demonstrates the use of the enzyme
Neuraminidase for probing low abundance sialated glycans from Trastuzumab. The low
abundance glycans that responded to Neuraminidase are denoted in Figure 6-A and
shown in Figure 6-B. Glycans were incubated with an in-capillary plug of
Neuraminidase for 5 minutes prior to separation and analysis with CE-LIF. Reproduced
with permission from [4].

4.3.7 Analysis with multiple in-capillary enzymes
To determine the complete glycan structure the sample can be treated sequentially with
multiple enzymes. Figure 4-7 and 4-8 show how two enzymes can be incorporated into
the capillary through multiple incubation and separations steps. In figure 4-7-A, the
glycan sample is injected into and incubated within a capillary containing only blanks
and no enzymes. The glycan is unaffected by these blanks and separated in the capillary
at the expected migration time. In figure 4-7-B, an enzyme that cleaves the terminal
outer-most glycans is introduced into the capillary. The glycan is injected into the
capillary and incubated, resulting in the enzymatic cleavage of that glycan residue. As a
result, the electrophoretic mobility of this glycan has changed, and now during separation
the glycan will have a different migration time. This process is continued in Figure 4-7-C
where two enzymes are injected, the second enzyme specific for the next level of glycans.
The glycan is injected, moved to the first enzyme plug and incubated, then moved to the
next enzyme plug and incubated. Two levels of glycan residues are removed, and the
glycan is then separated with a third migration time. During this process three different
experimental separations following incubation are conducted. Because the identification
of the glycan is dependent on migration time, it is critical that all methods utilize the
same injection/incubation/transfer protocol.
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Figure X demonstrates how multiple enzyme plugs can be used to probe the glycan for
sequential data. A glycan of interest is first separated in a capillary containing no enzyme
Figure
4-7 demonstrates how multiple enzyme plugs can be used to probe the glycan
(Figure X-A). The glycan is then separated through a capillary containing a single enzyme
for sequential
data.
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(Figure (Figure
X-C).
galactose
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7-B). The glycan is then separated in a capillary containing

two enzymes to remove two sequential layers of glycans, first the galactose residues,
then the glucosamine residues (Figure 7-C).

4.3.8 Use of multiple enzyme plugs to Characterize Major Glycans from
Trastuzumab
The enzymes used to characterize glycans from Trastuzumab were β1-4
galactosidase and β-N-Acetylglucosaminidase. A general schematic of the enzymes
placement in the capillary is seen in Figure 8. MOPS plugs placed between the enzyme
7
plugs and after the second plug, were used to prevent carryover between the enzyme
vials,August
and contamination
of the glycan sample. The Trastuzumab glycans were injected
Friday,
5, 2011
into the capillary, moved electrokinetically onto the first enzyme plug (10 kV 30 sec),
incubated for 10 minutes, moved to the second plug (10 kV 30 sec), then incubated for
another 10 minutes and separated. Figure 4-8 shows a blank reaction where both
incubations took place in pH 5 Citrate buffer plugs. The separation efficiency for G0F
was ~100,000 plates (vs 410,000) in spite of longitudinal diffusion due to the 20 minute
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total incubation time and because of the electrokinetic movement steps. When the
reactions took place with enzymes, the plate count decreased to ~35,000 following due
specific and nonspecific interactions with the protein.
When the glycan is subjected to only β1-4 galactosidase, it demonstrates that
three of the four major glycans from Trastuzumab (G1F, G1F´, and G2F) contain β1-4
terminally linked Gal residues, as shown in Figure 4-9-B. This experiment can also be
repeated with only β-N-Acetylglucosaminidase, to see if there are terminal GlcNAc
resides (shown in Figure 4-9-C). In this experiment the peaks affected include (G0F, G1F,
and G1F´). Because there are no exposed GlcNAc resides in G2F, this peak was
unaffected by the enzyme. Treatment with both enzymes, as shown in Figure 4-9-D, show
that all four peaks are reacted. If this reaction is continued, it will complete cleavage
down

to

a

fucosylated

mannose

core.
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Figure X demonstrates the use of multiple in-capillary plugs of enzymes to analyze glycans
from Herceptin.
Small discrete plugs of enzymes may be injected into the capillary prior to
Figure 4-8 demonstrates the use of multiple in-capillary plugs of enzymes to analyze
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before incubation. Once the glycan has been incubated in each of the plugs
it is separated and detected using CE-LIF. Reproduced with permission from [4].
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Figure 9 demonstrates the injection plug strategy described in Figure X, using the enzymes

!1-4 galactosidase and !-N-acetylglucosaminidase, either singly (Figures 9-B and 9-C) or

Figure 4-9
demonstrates
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(Figure the
9-D)injection plug strategy described in Figure 8, using the
enzymes β1-4 galactosidase and β-N-acetylglucosaminidase, either singly (Figures 9-B and 9Wednesday,
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2011Reproduced with permission from [4].
C)
or sequentially
(Figure
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This set of experiments can be expanded to include a number of other enzymes.
Because sialic acid is in such a low abundance in Trastuzumab, it was not necessary to
include the enzyme neuraminidase to the enzyme regimen. However, because this
enzyme is fast-acting, having incubation times of roughly 5 minutes, it is simple to add
neuraminidase into a three-enzyme

set of analyses. It is important to note that the

optimum pH for all exoglycosidases is similar (~pH 4.5 to pH 6). This means that, rather
than individual plugs of enzyme within the capillary, various enzymes may be combined
in cocktails for a single plug/ multiple reaction system. This method may provide
improved plate counts, as the number of incubation and move steps have decreased.
However, because this approach utilizes more total enzyme and total liquid handling, it
was not tested.

4.3.9 Benefits of Using In-Capillary Analysis for Multiple Enzyme Studies
The benefits of utilizing this method include drastically reduced amounts of
enzyme and sample, as well as time, as documented in Chapter 3. To emphasize the
benefits of in-capillary reactions specifically for multiple enzymes, a comparison to an
equivalent bench-top analysis must be made. In this system a glycan solution is being
probed with two enzyme solutions, and a limit of 20 µL volume size is required for
injection by an automated CE system (Beckman P/ACE MDQ). Figure 10 shows the
approaches that can be taken for multiple enzyme reactions, followed by analysis, either
serially (top figure) or in parallel (bottom figure). Serial bench top reactions involve the
full analysis of a sample, the enzymatic reaction of the entire sample followed analysis,
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followed by the final enzymatic reaction and more analysis. This method conserves the
total consumption of the glycan by using a single sample for multiple reactions but
increases the total experiment time. Additionally, sufficient analyses must be completed
before the next enzyme is used. Once an enzyme has been added to the glycan sample it
cannot be reused for repeated analyses of the prior steps. In contrast, parallel bench top
reactions utilize multiple samples or aliquots for multiple enzymatic reactions to incubate
simultaneously. Thus parallel analyses have faster experiment times, and samples that can
be reused, but consume significant amounts of glycan sample. It is also important to note
that the addition of enzyme in both parallel and series analyses affects both the glycan
concentration and the injection into the capillary. In contrast to these methods, utilizing
enzyme plugs in the capillary for on-line analyses utilizes a single glycan sample for
multiple, repeatable analyses. In-capillary sequencing uses ~2 nL of enzyme and 1 nL of
glycan per injection, allowing for numerous reactions to be completed without
compromising the original sample, making this method especially useful for volume
limited glycan samples.
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Benchtop Method 1: Serial Enzymatic Cleavage

incubate

20µL glycan

Analyze
with CE

incubate

20µL glycan +
XµL enzyme 1 +
XµL enzyme 2

20µL glycan +
XµL enzyme 1

Analyze
with CE

Analyze
with CE

Benchtop Method 2: Parallel Enzymatic Cleavage
incubate

Analyze
with CE

incubate

Analyze
with CE

incubate

Analyze
with CE

20µL glycan

20µL glycan +
XµL enzyme 1

20µL glycan +
XµL enzyme 1 +
XµL enzyme 2

Wednesday, October 12, 2011

Figure 4-10 demonstrates the various methods of bench-top enzymatic sequencing
using multiple exoglycosidase enzymes
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4.4 Conclusions
The incorporation of exoglycosidase enzymes and lectins is an appealing strategy to
probe complex solutions of glycans for structural characteristics. Phospholipid-assisted
capillary electrophoresis provides a highly efficient separations (~500,000 theoretical
plates) and utilizes small sample volumes in an automated method. The temperatureresponsive phospholipid separations material also provides a rapid, noncovalent method
to incorporate enzymes directly into the capillary. This method greatly reduces the
amount of enzyme and sample. Additionally the sample may be utilized for multiple
analyses. These methods were used to probe glycoprotein solutions of the immortalized
MCF-7 breast cancer cell line, determining whether glycans were high-mannose glycans
or had terminal mannose or galactose residues. Both high and low abundance glycans
were analyzed using these methods. The therapeutic antibody, Trastuzumab (Herceptin®)
was also analyzed using similar methods. The enzyme neuraminidase was used to
identify low abundance sialyated glycans, even though these glycans make up less than
1% of the total glycan content. The enzymes β1-4 galactosidase and β-Nacetylglucosaminidase were used both individually in different separations, and
sequentially in a single separation to determine the structure of the main glycans of
Trastuzumab.
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4.5 Future Directions:
Lectin Bind-and-Release using Phospholipid Assisted Capillary Electrophoresis: Glycan
analysis using lectins held within phospholipid is a powerful way to quickly probe
diverse solutions of glycans for those with a specific set of characteristics. Glycans that
have specificity to the lectin within the capillary, bind to the lectin and are also held
within the capillary, while the rest of the glycans continue to move through the capillary.
This means a selection of glycans sharing a common characteristic (i.e. high mannose or
branched mannose structures) can be retained for further analysis. If the plug of enzyme
is flooded with a glycan solution that disrupts the glycan binding and displaces these
glycan, the previously bound glycans can be subsequently released and separated for
further analysis, such as with CE-MS analysis.

Analysis of O-linked glycans and glycosaminoglycans: All studies completed in this body
of work centered on the analysis of N-linked glycosylation. However these are not the
entirety of glycans from protein sources. O-linked glycans attach via oxygen to serine and
threonine and have a wide variety of structures.
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